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Abstract 
 
Cancer treatment by adoptive immune cell therapy (AIT) is a form of immunotherapy that 
relies on the in vitro activation and/or expansion of immune cells. In this approach, immune cells, 
particularly CD8+ T lymphocytes, can potentially be harvested from a tumor-bearing patient, then 
activated and/or expanded in vitro in the presence of cytokines and other growth factors, and then 
transferred back into the same patient to induce tumor regression. AIT allows the in vitro 
generation and activation of T-lymphocytes away from the immunosuppressive tumor 
microenvironment, thereby providing optimum conditions for potent anti-tumor activity. 
The overall objective of this study is to: a) develop multi-modality (optical- and 
radionuclide-based) molecular imaging approaches to study the overall kinetics of labeled 
adoptively transferred T- lymphocytes in vivo, b) to non-invasively image and assess in-vivo, 
targeting and retention of adoptively transferred labeled T-lymphocytes at the tumor site.  
T-lymphocytes obtained from draining lymph nodes of 4T1 (murine breast cancer cell) 
sensitized BALB/C mice were activated in vitro with Bryostatin/ Ionomycin for 18 hours, and 
were grown in either Interleukin-2 (IL-2) or combination of Interleukin-7 and Interleukin-15 (IL-
7/IL-15) for 13 days, (cells grown in IL-2 called IL2 cells, and cells grown in IL7/15 called 
IL7/15 cells). In order to validate the methodology and to offer future clinical translation, both 
direct and indirect cell labeling methods were expanded and employed. The first method was 
based on direct in vitro cell labeling by lipophilic near-infrared (NIR) fluorescent probe, 1,1- 
dioctadecyltetramethyl indotricarbocyanine iodide, (DiR), followed by intravenous (i.v.) injection 
into BALB/C mice for multi-spectral fluorescence imaging (MSFI). The second method was 
based on indirect labeling of T- lymphocytes   through transduction of a reporter gene (cell 
cytoplasm labeling Herpes Simplex Virus type 1- thymidine kinase (HSV-1 tk). The product of 
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this reporter gene is an enzyme (HSV-1TK) which phosphorylates a radio labeled substrate 2-
fluoro-2-deoxy-1 β- D- arabinofuranosyl-5-iodouracil ([124I]-FIAU) for Positron Emission 
tomography (PET) imaging.   
ATP based cell viability assay, flow cytometry and interferon-γ (IFN-γ) ELISA were used 
to investigate if there are any changes in cell viability, proliferation and function respectively, 
before and after direct and indirect labeling. The results showed that cell viability, proliferation, 
and function of labeled 4T1 specific T-lymphocytes were not affected by labeling for direct 
labeling methods at DiR concentration of 320µg/ml. For the indirect labeling method, the viability 
and proliferation results showed that cell viability decreases as multiplicity of infectious (MOI) 
increases. In particular, at MOI of 10 almost all cells die 3 days post transduction. At MOI of 5, 
cells viability was ≤ 30% and at MOI of 2 was ≤ 60%.  Cell viability was 80% at MOI of 1. 
The results of optical imaging were as follows: when the recipient mice with established 
4T1 tumors were injected with DiR labeled 4T1 specific T-lymphocytes, the 4T1 specific T-
lymphocytes (IL2 cells) infused into tumor-bearing mice showed high tumor retention, which 
peaked 3 or 6 days post infusion depending on the tumor size and persisted at the tumor site for 3 
weeks.  In contrast, IL7/15 cells showed lower signal at the tumor site and this peaked on day 8. 
On the other case when 4T1 tumor cells were implanted 1-week post-infusion of labeled T-
lymphocytes. IL2 T-lymphocytes moved out of lymphoid compartments to the site of subsequent 
4T1 inoculation within two hours and peaked on day 3 and the signal persisted for 2 more weeks. 
In contrast with infusion of IL7/15 cells, the signal was barely detected and did not show a similar 
trafficking pattern as with IL2 cells. 
The results of the indirect labeling method, PET reporter gene (PRG) system (HSV-1tk / 
[
124
I ] FIAU ) showed that both IL2 and IL7/15 cells were successfully transduced as verified ex 
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vivo by real time PCR and western blot. T Cells transduction efficiency was assessed from cell 
uptake study in comparison to stable transduced Jurkat cells which have transduction efficiency of 
100 %.  Both IL2 and IL7/15 cells showed lower transduction efficiency (≤ 30%) compared to 
Jurkat cells.  Consequently, PET imaging did not show a detectable signal of transduced T cells in 
vivo.  Biodistribution study was carried out on day 3 post [
124
I]-FIAU injections. Results were 
consistent with the optical imaging results, except for IL7/15 cells. Transduced and untransduced 
IL2 and IL7/15 cells were labeled with DiR and injected ( i.v.) into Balb / C mice and then 
imaged by both imaging modalities (MSFI and PET) at the same time. MSFI images of 
transduced IL2 cell showed detectable signal starting from 2 hours, peaked at 72 hours and 
persisted up to 2 weeks, while IL7/15 cells were detectable at the tumor site starting at 24 hours, 
peaked at 72 hours and persisted up to 2 weeks. By the end of this study animals were dissected 
and tissue activities were counted using gamma counting and expressed as % Injected dose/gram 
of tissue (%ID/gm). Transduced IL2 and IL7/15 cells showed higher %ID/gm than other organs at 
lungs, liver, spleen, tumor, lymph nodes and bone/bone marrow. IL7/15 cells compared to IL2 
cells showed higher %ID/gm at same organs. Neither IL2 nor IL7/15 untransduced DiR labeled 
cells showed any activity at tumor site, and their activities at other organs was very low compared 
to transduced cells.  
To investigate whether labeled T-lymphocytes will localize at tumor metastases or not, 
and to study the difference in their migration patterns to the tumor site versus tumor metastases, 
4T1 tumor cells were successfully transduced with HSV-1tk  as confirmed by RT-PCR , western 
blot and cell uptake study. Transduced 4T1 cells were implanted in the right flank or in the 
mammary fat pad of the mouse. Serial PET imaging was carried out in the third and fourth week 
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post tumor implantation to know when the tumor will metastasizes. PET imaging showed only 
signal at the tumor site and no metastasis were detected. 
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Chapter One: Statement of Aims 
 
1.1Objectives 
 
           The overall objective of this project is to develop multi-modality in vivo imaging to study 
the kinetics of labeled immune cells particularly T-lymphocytes sensitized specifically to inhibit 
4T1 breast carcinoma tumor growth using Optical and PET imaging. This project intends to 
address the following questions: 
 
• What are the differences between T-lymphocytes grown in IL-2 versus IL7/15 in their 
migration patterns? (Where do they localize, when do they localize at tumor site, how long they 
persist, and do they retain their proliferation and functional abilities?) 
 
• What are the differences between direct and indirect labeling methods in terms of their 
specificity and sensitivity? 
 
 
• Do T-lymphocytes localize at the tumor metastases? What are the differences in T-cell 
homing between primary tumor and metastases?  
 
1.2. Specific aims 
1) To compare direct and indirect T-cell labeling methods, in terms of their specificity 
and sensitivity. 
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2) Using quantitative multi-modality (optical and PET) imaging the proliferation, 
trafficking and persistence of immune cells at various time points in vivo will be 
studied. 
3) To compare the trafficking and homing of T-cells grown in IL-2 versus cells grown in 
the combination of IL-7 and IL-15. 
4) To investigate the differences in trafficking and homing capabilities of labeled T-
lymphocytes at primary tumor versus tumor metastases. 
 
1.3. Significant and impact 
 Information from this project could provide direct in vivo data on delivery, localization, 
retention, and function of labeled immune cells within the context of adoptive immune cell 
therapy. This information is vital to understand the in vivo trafficking behavior to guide 
translation of immune cell therapy in the clinical setting. 
 
1.4. Innovation 
This work is novel in two important aspects: 
1) Employing two different imaging modalities to study the trafficking and homing of T-
lymphocytes grown in different cytokines (IL-2 versus the combination of IL7and IL-
15).  
2) Applying two different imaging modalities to image labeled T-lymphocytes and 
labeled 4T1 tumor in the same animal at the same time to know the difference in their 
migration pattern between primary tumor and metastases. 
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Chapter Two: Breast Cancer 
2.1 Biology of Breast Cancer     
  Breast cancer is the most common form of cancer in women, affecting one in every eight 
women in the United States [1].  Normal breast has six to nine overlapping sections, called lobes. 
Within each lobe there are many smaller lobules, which end in dozens of tiny bulbs that can 
produce milk. The lobes, lobules and bulbs are all linked by thin tubes called ducts. These ducts 
lead to the nipple in the center of a dark area of skin called the areola (figure 1). Fat fills the 
spaces around the lobules and ducts. There are no muscles in the breast, but muscles lie under 
each breast and cover the ribs. Each breast also contains blood and lymph vessels. The lymph 
vessels lead to small bean-shaped structures called lymph nodes. Clusters of lymph nodes are 
found in the axilla (under the arm), above the collarbone and in the chest [2].  
 
Figure 1 normal anatomy of the breast. Shows the normal structure of lobes, lobules and ducts.  
Lymph nodes are shown in the axilla region. Adopted from [2] 
 
 
Normal breast growth and development are regulated by the complex interaction of many 
hormones and growth factors include estrogens, progesterone, androgens, glucocorticoids, 
prolactin, thyroid hormone, insulin and insulin-like growth factors (IGF-1 and IGF-2), fibroblast 
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growth factors (FGF), and epidermal growth factor (EGF)/transforming growth factor alpha 
(TGF-α) [3]. The interaction of growth factors, cytokines, and hormones with specific membrane 
receptors triggers a cascade of intracellular biochemical signals, resulting in the activation and 
repression of various subsets of genes. Several of these hormones have been shown to play an 
active role in the development of breast cancer.  For example, estrogen stimulates breast cell 
division, which can increase the risk of breast cancer. Furthermore, breast cells are not fully 
mature in girls and young women who have not had their first full-term pregnancy [2]. Breast 
cells which are not fully mature bind carcinogens more strongly and they are not as efficient at 
repair DNA damage as mature breast cells. Breast cancer, like any other cancer, takes years to 
develop, and it can take place at any part of the breast anatomy. In terms of histology, breast 
cancers are heterogeneous, they are mainly ductal, but also lobular, mixed ductal and lobular, 
cribriform, mucinous and tubular carcinomas [4]. Figure 2 illustrates the stages of breast cancer 
development at the ductal part.  For some reason mostly DNA mutations in any of breast genes, 
normal cells divide rapidly and causes ductal hyperplasia, which with time  develop to atypical 
ductal hyperplasia then ductal carcinoma in situ (DCIS) and in then becomes DCIS with 
microinvasion (DCIS-MI).   
2.2. Subtypes of breast cancer 
Based on the hormones and growth factor regulations, breast cancer has several subtypes, the 
most commons are: 
 
Basal (Triple Negative) Breast Cancer 
The basal subtype is also called “triple negative” cancer, because the cells are negative for three 
common markers: estrogen receptors (ER), progestin receptors (PR), and human epidermal 
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growth factor receptor-2 (HER-2). Although the basal subtype is only found in about 15% of 
breast cancers, it has been shown to be aggressive, unresponsive to treatment and, ultimately, 
indicative of a poor prognosis [5]. Basal-type breast cancer is diagnosed more often in African 
American women than in Caucasian women in the United States [6]. Compared to other subtypes, 
it is poorly defined by mammography and best detected by MRI. It is also often detected as grade 
III, tumors, resulting in more aggressive and poor overall prognosis [7]. 
HER-2 Over-expression Breast Cancer 
As the name suggests, HER-2 over-expressing tumors have extra copies of the HER-2 gene and 
over-produce the resulting growth-enhancing protein. This protein is overexpressed in about 20% 
of breast cancers [8]. Biologically, the up-regulation of HER2 gene is associated with increased 
proliferation, angiogenesis, and invasiveness [9].  
These tumors tend to grow quickly but are responsive to targeted drug treatment with compounds 
like, Trastuzumab and more recently other drugs such Lapatinib and Pertuzumab   which have 
shown specific activity against HER2 positive breast cancer and an increase in the median 
survival up to 2 years [10].  
Luminal A and B Breast Cancers 
Luminal A and B subtypes are both estrogen-receptor-positive (ER+) and low-grade, with luminal 
A tumors growing very slowly and luminal B tumors growing more quickly. Luminal A tumors 
have the best prognosis. Several studies have been conducted using microarray technology, to 
study breast cancer subtypes showed that, for different gene expression profiles, prognosis and 
treatment response vary for different subtypes [11]. Luminal B compared to luminal A shows 
lower expression levels of ER or estrogen-regulated genes, lower or no progesterone receptor 
(PR) expression, higher tumor grade, higher expression of proliferation-related genes and 
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activation of growth factor receptor signaling pathways. Also luminal B tumors have lower 
sensitivity to endocrine treatment and higher sensitivity to chemotherapy than luminal A tumors 
[12]. 
 
Figure 2 breast cancer (DCIS-MI) developments. Ductal hyperplasia develops to Atypical ductal 
hyperplasia then ductal carcinoma in situ. With microinnovation at late stages become ductal 
carcinoma in situ with microinvasion (DCIS-MI).adopted from [2] 
 
2.3. Treatment of breast cancer 
Treatment options of breast cancer include; surgery, chemotherapy, radiotherapy, hormone 
therapy and immunotherapy. The choice of treatment is based on the tumor subtype and stage of 
the disease. Several studies showed that, combination of treatment options (adjuvant therapy) is 
more effective than single agent therapy. Radical mastectomy (local surgery) followed by 
radiotherapy produce local control. Chemotherapy is preferred in cases of receptor-negative 
tumors, acquired resistance to hormonal therapy and aggressive visceral metastatic diseases. 
Primary chemotherapy is increasingly used in the treatment of locally advanced tumors with 
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increased rates of breast-conservative surgery. In case of hormone receptor positively and absent 
of visceral, life-threading disease, endocrine manipulation is the treatment of choice [13]. 
Endocrine manipulation usually done, using Tamoxifen or ovarian ablation or both (both are more 
effective), for postmenopausal patients [13].  Immunotherapy of breast cancer as an adjuvant 
therapy, based on active immunizations or passive therapy has in some instances been shown to 
prevent tumor recurrence and improve patient survival [14]. The rationale behind immunotherapy 
for breast cancer can be highlighted in two points: i) Breast screening provides an opportunity to 
employ immunotherapy in early stage of  tumor development, when the immunosuppressive 
effects of the tumor are relatively low, ii) Breast cancer expresses specific tumor antigens which 
can be utilized to ex vivo engineer T-lymphocytes to yield  tumor specificity [15].  
 
2.4. Adoptive Immune cell Therapy (AIT)   
The first observations that the immune system has antitumor effects against sarcoma tumors 
were noticed in 1890s by William Coley [16]. After years later, researchers noticed that, the major 
mediators inducing this effect are T cells [17] and based on this rationale the concept of Adoptive 
cellular immunotherapy (ACI) or Adoptive cell transfer (ACT) or Adoptive immune cell therapy 
(AIT) was introduced [18]. The immune response to genetic changes in transformed tumor cells 
appears from the accumulation of antigen-specific T cells within the tumor and draining lymph 
nodes [19]. T-cells function as part of the adaptive immune system,  to attack and kill tumor cells; 
unfortunately tumors keep growing because the anti-tumor immune response is either not 
sufficiently strong to eliminate tumor cells or the anti-tumor immunity is suppressed by regulatory 
cells or other factors secreted by the tumor.   In the past, the immune system has been thought to 
play a role in the recognition and elimination of nascent malignancies through so called 
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immunosurveillance [20]. However, because of a lack of concrete evidence, the hypothesis of 
immunosurveillance had been abandoned and recently a new concept called immunoediting 
which is comprised of three phases; elimination, equilibrium and escape phase, has been 
demonstrated: 
1. Elimination phase: during the elimination phase, T cells (CD4, CD8, NK and γð cells) 
appear to recognize transformed cells early in the development of tumors; the mechanism 
of this recognition is not fully understood but sufficient to kill some tumors.  
2. Equilibrium phase: in the equilibrium phase, tumors that are not completely eliminated 
undergo a selection process termed immunoediting whereby tumor cells “ hide” their 
antigens by weak expression or endocytosis, thereby allowing tumor cells to escape 
immune response, survive and accumulate mutations.  
3. Escape phase: in the escape phase, when tumors are fully developed and can be detected, 
they can   promote immune suppression through recruitment of suppressive cells such as 
regulatoray T cells (T-reg) and production of suppressive cytokines as IL-10 and TGFß 
[21- 23].   
AIT could overcome the limitations described above, because it relies on enhancing the 
patient’s immune system ex vivo isolated from the suppressive environment of tumor cells. It is 
based on isolation, expansion, and re-infusion of large numbers of tumor specific patient’s own 
immune cells, particularly cytotoxic T lymphocytes, to induce tumor regression. Potentially, AIT 
could be an effective treatment strategy, because it facilitates direct interaction between immune 
cells and tumor cells without adverse effects on normal cells.   
32 
 
In order to understand the dynamics and the process of AIT and to monitor the migration, 
localization and retention of labeled immune cells, in vivo studies, in live subjects and within 
the intact physiological environment, are needed. 
 
2.5. Adoptive Immune Cell Therapy (AIT) of breast cancer 
 Breast cancer is a systemic disease with primary local tumor and disseminated metastatic 
disease. The aim of Surgery, chemotherapy and radiotherapy is to induce primary tumor 
regression over the specific treatment regimen.  Clinically in breast cancer, micrometastatic tumor 
can be eliminated using hormone therapy, chemotherapy and AIT [24]. In wide variety of breast 
cancer, the tumor-infiltrating T lymphocytes, particularly type-1 helper T cells (Th1) and 
cytotoxic T lymphocytes cells (CTL) are correlated with the absence of metastatic invasion and 
increased overall survival rates [25] 
Several studies in AIT of breast cancer highlighted that, the success of AIT is based on the 
ex vivo activation of T cells.  It occurs through two stages: an ex vivo stage involves incubating T-
lymphocytes with appropriate antigens or non-specific activators (either antibodies or chemicals) 
and growth factors that mimic the in vivo activation environment. One such environment has been 
achieved by pulsing T-lymphocytes in Bryostatin 1 and Ionomycin, which mimic TCR signaling 
to trigger the T-cell activation pathway. Bryostatin 1  activates Protein kinase C (PKC) and 
Ionomycin increases intracellular calcium, and together they lead to activation of transcription 
factors: nuclear factor Kβ (NF Kβ) and nuclear factor of activated T cells (NFAT) respectively. 
These transcription factors move to the nucleus and initiate the transcription of IL-2 and other 
genes which are essential for T-cell proliferation [26-28]. The in vivo stage through the interaction 
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between MHC–peptide (Major Histocompatibility Complex) expressed on antigen- presenting 
cells e.g. dendritic cells (DCs) to initiate T-cell activation [28]. 
The success of AIT relies on manipulation of tumor specific T-lymphocytes to produce 
large numbers of these cells as well as optimization of effector functions. AIT allows the 
generation and activation of T-lymphocytes away from the suppressive tumor environment 
providing the optimal environment for anti-tumor responses [29]. One example of AIT success in 
the treatment of advanced metastasized breast cancer patients was shown by Christoph Domschke 
and his colleagues [30]. They demonstrated that, adoptively transferred T-cell clones (tumor 
antigen-reactive type-1 T cells) persist in vivo and preferentially localize to tumor sites and 
mediate an antigen-specific immune response characterized by metastases regression and 
significantly longer overall survival in 7 of 16 patients. Another study showed that the re-infusion 
of T lymphocytes, engineered to express Tumor- specific TCR, induce regression in 13% of 
patients [31]. The question is; why some patients respond to the therapy and some do not? 
Tracking the movement, proliferation and viability of re-infused tumor specific T-lymphocytes by 
multi-modality imaging in serial images at different time points during the treatment could define 
the parameters that lead to successful AIT. Therefore, In order to understand the dynamics and the 
process of AIT, noninvasive and repetitive  multimodality imaging of   labeled immune cells 
provides the opportunity to study in vivo trafficking, homing, tumor targeting, activation, 
proliferation and persistence of  transferred labeled cells [32].  
This thesis aims to contribute  new knowledge in this context, by direct in vivo imaging 
of pathways associated with the process of AIT. 
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Chapter Three: Molecular Imaging of AIT 
3.1. Introduction 
Molecular imaging is the visualization, characterization, and measurement of biological 
processes at the molecular and cellular levels in humans and other living systems [33]. The main 
advantage of in vivo molecular imaging is its ability to characterize diseased tissues without 
invasive biopsies or surgical procedures and with this information in hand; more personalized 
treatment planning can be applied [34].  Different imaging modalities are used for molecular 
imaging, including optical (fluorescence and bioluminescence), positron emission tomography 
(PET), single photon emission computed tomography (SPECT), magnetic resonance imaging 
(MRI) [35] and more recently the development of  Multi Spectral Optoacoustic Tomography 
(MSOT) imaging [36]. Optical imaging utilizes light photons at different wavelengths at visible 
and infrared ranges resulting from fluorescent and biolumencent events. The application of optical 
imaging is limited in humans because the wavelength of the probes emitted in the biolumencent 
or fluorescent processes are too weak to penetrate deep and thick layers of tissues that are blood-
rich tissues. In optical imaging, low noise images require acquisition times of about 5-10 minutes, 
which may increase the thermal noise, but this can be reduced with thermo-electric cooler. 
However, this technique is widely used in molecular imaging due to its simplicity and cost 
effectiveness [37]. Radionuclide-based imaging methods (PET and SPECT) are based on gamma 
(γ)-positron and single photon emitting radionuclides used to radiolabel probes specific for the 
process under study. Clinical PET has spatial resolution of about 5mm, while animal micro-PET 
resolution is about 1.5 mm [38].  PET compared to SPECT has higher sensitivity and both are 
independent of tissue depth.  
MRI is widely used for soft tissue imaging. The physics of MRI is based on the alignment 
of the protons to magnetic field (MF) when they are placed in strong MF and form longitudinal 
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magnetization. Radio frequency (RF) pulses are used to alter the protons alignment and tilts the 
longitudinal magnetization to be transversal magnetization , when the RF is turned off, the 
protons realign with magnetic field again and generate an electromagnetic flux that provide 
information about tissues under study. Due to this, the image acquisition time is long but high 
spatial resolution and good image contrast is achievable [39].  
Table-1 summarizes the advantages and limitations for each imaging modality and their 
application in cell-based imaging and trafficking. The role of molecular imaging in AIT is to 
optimize and maximize the chance of AIT success for each individual patient as the cells are the 
patient’s own cells [40]. A number of variables need to be optimized for each individual patient to 
obtain the desired outcome of AIT.  As an example of these variables, is the number of cells  to 
effectively treat a certain tumor. Measuring tumor size and injecting different numbers of cells 
will provide information about the effective number that has to be injected for each individual 
patient. 
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Table: 1 demonstrated some characteristics of each modality regarding to their use in cell therapy 
monitoring and imaging. 
[
18
F]-FDG =[ 
18
F] fluoro-2-deoxy-d-glucose, [ 
18
F]-FHBG=  [ 4-
18
F- fluoro-3- (hydroxymethyl) 
butyl] guanine,  
18
F-FEAU= 2
’
- 
18
F- fluoro-2
’
-deoxy-1-beta-d-arabinofuranosyl-5-ethyluracil, 
124
I-
FIAU = 2
’
-fluoro-2
’
- deoxy- 1-beta-D-arabinofuranosyl-5- 
124
I- iodouracil, 
64
Cu-PTSM= 
64
Cu-
pyruvaldehyde-bis (N
4
- methylthiosemicarbazone), 
99m
Tc-HMPAO= 
99m
Tc- 
hexamethylpropyleneamine oxin 
Modality Imaging probe 
Used to track 
cells 
Advantages Limitations Application in 
AIT 
PET 
18
F-FDG,  
18
F- FHBG 
18
F-FEAU,  
124
I-FIAU 
64
Cu-PTSM 
89
Zr- Oxine 
Unlimited depth 
penetration,  
Whole-body imaging, 
quantitative data, 
anatomical and 
physiological 
information when 
combined with CT 
 Radiation exposure 
Expensive, long 
acquisition time (minutes 
to hours), low spatial 
resolution when used 
alone 
 
Has been used 
to label 
directly or 
indirectly  
T cells, DC  
and other 
immune cells 
for monitoring 
cell 
localization 
trafficking 
And 
persistence 
 in vivo in 
animals and 
human. 
 
 
SPECT 
111
In-Oxine, 
 
99m
Tc-HMPAO, 
123/125/131
I- FIAU 
Unlimited depth 
penetration,  
Whole-body imaging, 
quantitative data, 
 anatomical and 
physiological 
information when 
combined with CT 
  Quantitative, unlimited 
depth penetration, Low 
spatial resolution and 
ionizing radiation. 
MRI Iron oxide 
nanoparticles 
(SPIO),  
Gadolinium- 
chelates 
High spatial resolution, 
Unlimited depth 
penetration, no ionizing 
radiation,  
Whole-body imaging, 
Excellent soft-tissue 
contrast 
Expensive, 
Limited sensitivity 
(require large amount of 
the probe which might be 
toxic to the subject under 
study) and long  
acquisition time 
Optical 
Imaging  
Organic dyes, 
fluorescent 
proteins, 
quantum dots 
and luciferase in 
bioluminescence 
imaging 
Fast, 
simple ,inexpensive, 
quantitative, high 
sensitivity, and no 
ionizing radiation 
 
Limited depth penetration 
(≤ 1cm) 
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3.2. Labeling approaches 
 
Molecular imaging of immune cells requires labeling of these cells directly or indirectly. 
Direct labeling is based on the incubation of  activated and in vitro expanded immune cells in the 
labeling probe for a few minutes (10-30 minutes) followed by  washing then reinfusion into a 
subject under examination, followed by serial images at different time points. This method 
depends on the ability of a cell to retain the label.  The advantages of direct labeling approach are 
relatively easy, low expenses, and well established methods. However, this method does not allow 
Long term monitoring of labeled cells   because the label is lost or diluted as a result of  apoptosis 
or mitosis respectively [41,42]. 
Indirect labeling is achieved through transduction of immune cells with a reporter gene, 
for example; Herpes Simplex Virus type 1-thymidine kinase (HSV-1 tk, cell cytoplasm labeling). 
The product of this reporter gene is an enzyme that phosphorylates a radio-labeled substrate 2-
fluoro-2-deoxy-1 β- D- arabinofuranosyl-5- 124I  iodouracil [ 124I ]-FIAU  for PET imaging.  
Figure 3 demonstrates the strategies of direct and indirect labeling approaches. Figure 4 showed 
schematic representation of the indirect labeling mechanism and trapping of the labeled probe by 
the cell. 
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Figure 3 direct and indirect labeling strategies. Direct labeling (1- immune cells harvested from 
donor animal  and ex vivo activated and expanded, 2- cells labeled with radio or optical probe, 3-  
cell reinfused to same strain host animal bearing same tumor, 4- serial imaging over specific 
period of time preformed). Indirect labeling (1- immune cells harvested from donor animal and ex 
vivo activated and expanded, 2- cells transduced with reporter gene (RG) using viral vector 
carrying RG, waiting few days for gene expression and RG enzyme production, 3- transduced 
cells reinfused to same strain host animal bearing same tumor, 4- a substrate of the RG enzyme 
injected and serial imaging over specific period of time preformed) [43]. 
 
 
Direct Labeling method Indirect Labeling method 
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Figure 4 the indirect labeling method from cell transduction to imaging. Viral vectors are used to 
transduce cells with specific reporter gene (RG), once the transduction is established and the RG 
is integrated into cell genome, transcription and translation controlled by specific promoter occur. 
The product of RG translation is an enzyme which will phosphorylate specific probe to be trapped 
in the transduced cells [44].  
 
 
 Indirect labeling method allows for reliable, stable and harmless visualization of cellular 
trafficking, persistence, proliferation and function at target site. Furthermore, it permits long-term 
cell monitoring (months) if the RG is integrated into target cell genome [45]. However, this 
approach is limited by targeting or delivery of the RG to cell under transduction, integration, 
activation, amount or level of RG (transduction efficiency), RG expression and persistence over 
time and immune response problems.  
A number of RGs have been developed for radio and non radiotracer (Bioluminescence) imaging, 
(listed in table 2). Three categories are identified based on the RG product: transporter, enzyme 
and receptor.  The transporter group includes the sodium iodide symporter (NIS) and the 
norepinephrine transporter (NET). The enzyme classification includes herpes simplex virus 1 
thymidine kinase (HSV1-tk) gene and the HSV1-tk mutant (HSV1-sr39tk). The receptor group 
Gene delivery  
by viral vector 
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includes Specific membrane receptors (SSTrs), which mediate the various actions of somatostatin, 
which is a peptide that inhibits the release of growth hormone. RG applications initially were in 
gene therapy and adoptive cell-based therapies. Recently, noninvasive in vivo reporter gene 
imaging is likely to include: (a) quantitative monitoring of gene therapy vectors for targeting and 
transduction efficacy in clinical protocols by imaging the location, extent and duration of 
transgene expression; (b) monitoring of cell trafficking, targeting, replication and activation in 
adoptive T-cell and stem/progenitor cell therapies; and (c) assessments of endogenous molecular 
events using different inducible reporter gene imaging systems [46]. 
 
Table 2 RGs classifications based on their products and their corresponding probes [46]. 
Class RG RG probe (RGP) Imaging modality 
Receptor 
 
 
SSTr2 
 
[ 
111
In] DTPA-Octerotide 
[ 
99m
Tc ] P829 
[ 
99m
Tc ] P2045 
 
SPECT 
 
Transporter 
 
 
 
 
NIS 
 
 
NET 
 
 
 
[ 
99m
Tc ] Demotate1 
[ 
124
I] Iodine 
 
[ 
99m
Tc ] Pertechnetate 
[ 
131
I] Iodine 
[ 
123
I] MIBG 
 
SPECT 
PET 
SPECT 
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Enzyme 
 
 
 
HSV1tk 
HSV1-sr39tk 
 
 
 
 
 
 
 
 
 
Firefly luciferase 
Renilla Luciferase 
 
 
 
luciferin 
coelenterazine 
 
[
123,124,125,131
I ]-FIAU 
[
18
F ]-FIAU 
[
123,124,125,131
I ]-IVDU 
 [
123,124,125,131
I ]-VFAU 
[
123,124,125,131
I ]-IVFRU 
[
18
F ]-FEAU 
[
18
F ]-FHBG 
[
18
F ]-FHPG 
 [
18
F ]-FIRU 
[
18
F ]-FUdR 
 
PET and SPECT 
PET 
PET and SPECT 
PET and SPECT 
PET 
PET 
PET 
PET 
Bioluminescence 
Bioluminescence 
 
 
3.3. PET imaging  
3.3.1. Decay and annihilation  
PET imaging was developed several decades ago. Currently, it is playing an important role in 
the diagnosis, staging and therapy monitoring of different types of cancer [47]. PET probes or 
tracers are radiopharmaceutical compounds labeled with a positron-emitting radionuclide. The 
most widely used PET tracer is the fluorinated analogue of glucose fluorodeoxyglucose (FDG) 
labeled with 
18
F due to the increased utilization of glucose by brain and heart normal cells and 
also malignant cells. Positron emitting radionuclides are neutron- deficient isotopes which reach 
stability through nuclear transformation of proton to neutron (figure 5a) with emission of positron 
(positive electron e
+ 
) and neutrino. The maximum energy of emitted positron depends on the 
isotope, it ranges from 0.6 MeV of 
18
F to 3.4 MeV of 
82
Rb [51]. The emitted positron travels a 
certain range depending on its energy, which will be lost through interactions with surrounding 
tissues until it annihilates with an electron (figure 5b). The result is 2 annihilation gamma rays, 
0.511 MeV energy each emitted in opposite directions (about 180
0
 from each other) and detected 
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in coincidence within time window of 2τ ns.  The distance traveled by the positron from the decay 
event to the annihilation event (positron range) and the non-linearity of the annihilation gamma 
rays cause loss of spatial resolution that cannot be recovered during image reconstruction.  
3.3.2. Coincidence events 
Three coincidence events in PET are identified as: true, scattered, and random (figure 6). True 
coincidence occurs when both photons from an annihilation event are detected by detectors in 
coincidences and no other event is detected within the time window. A scattered coincidence 
occurs when at least one of the detected photons undergoes Compton scattering prior to detection. 
Scattered coincidences add background to the true coincidence, decreases image contrast and 
cause overestimating of the isotope concentration. Random coincidences occur when two photons 
are not arising from the same annihilation event and detected within the convenience time 
window [48]. 
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Figure 5 demonstrations of the positron emission and annihilation. 5a An unstable nuclide 
with an extra proton which decays into neutron, positron and neutrino. 5b positron travels 
a certain distance depends on its energy then annihilates with an electron and the result 2 
gamma rays (511Kev each) emitted in opposite direction about 180
0
 away from each 
other. 
 
 
 
 
Figure 6 A true coincidence detection occurs when the two gamma rays are detected from one 
annihilation event in the time window. B if at least one of the gamma photons under goes 
Compton scattering, and both photons still detected in the time window, scattered coincidence has 
occurred. C random coincidence occurs when both photons detect in the time window and are 
from deferent annihilation events.   
True Coincidence                   Scattered coincidence          Random coincidence                                                                               
(a) 
(b) 
A B C 
180
0 
0.511 MeV
 
0.511 MeV
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3.3.3 PET Radionuclides used for imaging in AIT 
Avariety of radionuclides has been used to track and monitor labeled cells in vivo. The common 
radionuclides are listed in table 3. 
18
F is widely used as PET radionuclide in many applications 
due to its short half-life and fast clearance from subject under study. However, it requires rapid 
radiochemistry and immediate delivery. 
64
Cu and 
124
I have relatively longer half-lives making 
them more acceptable for long term tracking and monitoring of labeled cells. 
Table 3 Isotopes and examples of their radiotracers used to track immune cells for PET imaging.  
Nuclide & 
Radiotracer 
Mechanism of cell labeling Half-life Decay modes Maximum 
positron 
energy (MeV) 
and yield (%) 
production 
18
F-FDG Cross cell membrane by 
transporters 
109.8 
minutes
 
EC, ß
+
 0.634 
(96.7 %) 
18
O (p ,n)
 18
F 
 
20Ne (d, α) 18F 
64
Cu-PTSM Lipophilic cross cell 
membrane through passive 
diffusion 
12.7 
hours 
EC, ß
+ 
, ß
-
 0.653 (17.4%) 
62
Ni (p, n)
 64
Cu 
124
I- FIAU Trapped by cell through 
phosphorylation by viral 
thymidine kinase produced 
by  transduced cells 
4.18 days EC, ß
+
 2.138 (23.0%) 
126
Te (p,3n)
 124
I 
89
Zr-Oxine Lipophilic cross cell 
membrane through passive 
diffusion 
3.26 days ß
+
 1.74 (12%) 
89
Y(p, n) 
89
Zr 
 
3.4. Optical Imaging 
3.4.1. Introduction 
         Optical imaging is noninvasive in vivo imaging with light photons detected by charged 
coupled device (CCD) detectors made from silicon crystals which have high sensitivity to light. 
Two common types of optical imaging are well-known in the realm of molecular imaging; 
fluorescence and bioluminescence imaging. In the Fluorescence imaging an excitation light of one 
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wavelength in the range between 395-600 nm illuminates the subject under study and an emission 
light with wavelength higher than the excitation wavelength detected by CCD detector [49]. The 
use of near-infrared probes (spectrum range 700-1000nm) for optical imaging maximizes tissue 
penetration because hemoglobin and water which are the major absorbers of light have lowest 
absorption coefficients in the infrared range. In bioluminescence imaging only the emission light 
is detected by CCD detectors and no excitation light is used in this technique. The most 
commonly used bioluminescence probes are reporter genes, Firefly or Renilla Luciferase ( FLuc 
or RLuc respectively). Their substrates are Luciferin for FLuc and Coelenterazin for RLuc.  In 
case of using FLuc,  cells  transfected by FLuc  gene and express the Luciferase enzyme that will 
oxidize the Luciferin ( given as i.v. injection at different time points) in the presence of oxygen, 
ATP and magnesium (Mg
2+
) to produce Oxyluciferin and light which will be detected by CCD 
camera to be quantified and process image reconstruction. The main advantage of 
bioluminescence imaging is that it can detect very low signal and the background signal is very 
low. But the efficiency of the transmission light is limited and depends on the tissue type. Skin 
and muscle have highest transmission, whereas highly vascular organs such as liver and spleen 
have lowest transmission because of the absorption of the light by oxyhemoglobin and 
deoxyhemoglobin [50 ]. 
3.4.2 Multi-spectral fluorescence imaging (theory and concepts) 
3.4.2.1. Florescence (definition, emission and excitation spectrum) 
         Fluorescence is the emission of light that occurs rapidly (around one million of a second) 
after illumination. When the light emission takes longer time is called phosphorescence. Two 
major problems are encountered with fluorescence measurement: first, fluorescence is emitted by 
the fluorescent molecule such as dyes in all directions and most imaging systems are designed to 
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capture light coming from particular direction. Second, it is difficult to obtain identical excitation 
of the total fluorescent molecules in the subject under study [51]. Fluorescent materials always 
emitted light with longer wavelength than the exciting light. The differences between wavelengths 
of emission and excitation lights is called Stoke’s shift. The range of the excitation wavelengths 
known as absorption spectrum, while the emitted light covers range of wavelengths known as 
emission spectrum. In most cases there is overlap between the excitation and the emission 
spectrum. 
3.4.2.2. Autofluorescence (definition and multispectral analysis solution) 
        Some biological materials such as vitamins, hormones, and enzymes are naturally 
fluorescent. Resulting strong fluorescent signals interfere with the signal of specific labeling 
probe and cause unwanted background which known as autofluorescence. Animal skin, fur and 
food, particularly if the food contained Chlorophyll, are strong sources of the autofluorescence 
signals [52]. Excitation and emission filters are used to reduce this problem. Both filters should be 
chosen to match the maximum excitation and emission wavelengths of a specific probe. 
Multispectral imaging systems provide a unique solution to the autofluorescence problem using 
multispectral analysis. It is based on the fact that all fluorescent materials produce specific 
emission spectra. Multispectral analysis generates spectral curves for the various fluorescent 
materials and autofluorscence curves in the subject under study. Based on this technique a series 
of images are captured called image cube taken at specific wavelength. Using sophisticated 
algorithms, the contribution of autoflourscence to the image can be removed, and specific 
fluorescence spectra for specific probe are separated.  
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3.4.2.3. Multi-spectral imaging system (Maestro2)  
 
 
 
The multi-spectral imaging system used in 
this project is shown in figure 7. The various   
components of the system  include, high-
resolution, scientific- grade CCD imaging 
sensor, solid-state liquid crystal (LC) 
wavelength tuning element, spectrally 
optimized lens and internal optics, an 
excitation light source and emission filter 
assembly.  The system has a control panel 
with switches for the excitation lamp, shutter, 
and white interior lights. It also displays the 
system statues such as the interior temperature 
and current filter wavelength.   
Figure 7 Multispectral fluorescence imaging system (Maestro2 at CMI/VCU). Wavelength range = 
500-950 nm; FOV = Max 3 mice; Spectral Unmixing and Dynamic Contrast Enhancement (DyCE™) 
allows quantitation of temporal biodistribution of fluorescent markers at much earlier time points (first 
few seconds following injection).  
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3.5. Labeling and imaging of T lymphocytes (literature review) 
Noninvasive in vivo imaging of adoptively transferred T-lymphocytes requires an 
effective and mild labeling methodology and the right imaging technology direct labeling enables 
the imaging of cells labeled ex vivo and reinfused into the patient or subject who is being 
examined. Radionuclide based direct labeling probes for SPECT/PET imaging includes include, 
[
111
In]-Oxine, [
18
F-]FDG,[
99m
Tc]-HMPAO, and[
64
Cu]-PTSM. These have been used to monitor 
the migration of T-lymphocytes in vivo [53, 54].  However, these techniques do not permit long 
term monitoring due to the short physical half-life of the radionuclides, relatively low level of 
radioactivity per cell, and in certain instances, are limited by significant cell toxicity [55]. On the 
other hand, indirect labeling utilizes imageable reporter protein/probe combinations and rely on 
the ex vivo transduction of a relevant reporter gene into the immune-competent cells. Following 
reinfusion of the transduced cells into the subject, the product of the reporter gene can be imaged 
by injecting a suitable radiolabeled substrate. Herpes Simplex Virus Type-1 Thymidine Kinase 
(HSV1-tk) is such a PET reporter gene (PRG) and is one of the most commonly used indirect 
methods to image adoptively transferred T-lymphocytes in animals and patients, and it can be 
imaged with various substrates such as[
124
I]-FIAU, [
131
I]-FIAU, [
18
F]-FEAU and [
18
F]-FHBG 
[58,59]. The sodium iodide symporter (NIS) is another reporter gene that has also been evaluated 
for imaging cells of the immune system in immortalized macrophage cell lines genetically 
engineered to express NIS and GFP (RAW264.7/hNIS-GFP) [56]. Using [
124
I-NaI PET imaging, 
these investigators monitored macrophage migration towards inflamed tissue. In addition to 
124
I, 
99m
Tc04, 
123
I, 
125
I, [
18
F]-tetrafluoroborate can also be used as substrates for NIS [57].  
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Radionuclide based methods are useful in the clinic due to the ability to image signals 
from deep tissues. However, the logistics of radionuclide techniques are more demanding, which 
makes them less cost effective for preclinical investigations. Non-radioactive agents, such as 
fluorocarbon-based probes, have also been used for efficient direct ex vivo labeling of cells, and 
used in conjunction with 
19
F MRI for in vivo detection and imaging [58].  This method, which 
involves the use of an autologous dendritic cell vaccine to treat colorectal cancer, is currently 
being evaluated in humans (personal communication). This represents the first clinical trafficking 
study of a live cell cancer vaccine which has been visualized by MRI in the United States.  
 
On the other hand, optical methods are relatively easy, require simpler imaging equipment 
and are cost effective, but are not very useful in the clinic due to the lack of effective technology 
that can detect optical signals from deep tissues. However, optical labels, both direct and indirect, 
could be very useful for research and development of various strategies aimed at improving 
immune cell therapy. One cost effective approach is to use optical reporter proteins such as firefly 
or renilla luciferase to label the cells and monitor them by optical imaging [59, 60]. However, 
these are currently limited to animal models and their success relies on the successful stable 
transduction of the reporter gene and the persistence of the reporter gene expression over time. A 
combination of direct labeling strategy and optical imaging methodology would be ideal, in terms 
of simplicity and cost effectiveness, for monitoring cell trafficking in preclinical studies. This 
could be extended to clinical investigations if a suitable imaging component such as 
124
I or 
19
F is 
included in the direct cell labeling strategy.  
Studies describing optical imaging of directly labeled immune cells is quite limited. 
However, using ex vivo imaging and other in vitro protocols, several DNA-binding, cytoplasmic, 
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covalent coupling or membrane inserting fluorescent dyes have been investigated for direct 
labeling of T lymphocytes to track lymphocyte migration and proliferation [61]. Due to 
interference from autofluorescence and tissue absorbance, most of these dyes are not ideal for in 
vivo optical imaging and their use is limited to ex vivo detection. The optical imaging window is 
primarily limited by absorption, due to either blood at short wavelengths or water at long 
wavelengths. This could be overcome with the use of near-infrared dyes (NIR) that will allow 
deep tissue signal localization [62]. The red/NIR tissue optical window between 600 and 1300 nm 
is the spectral region where light has its maximum depth of penetration in tissues due to minimal 
absorption and scattering. Among the various options available for direct labeling, the cell 
membrane dyes retain the signal for relatively longer periods than DNA-binding, cytoplasmic or 
covalent coupling dyes [63]. Therefore, a combination of NIR based fluorescent cell membrane 
dyes would offer a direct labeling method for monitoring cell trafficking while exploiting high 
sensitivity, simple labeling technique, decreased autofluorescence and relatively low costs.  
 In this project multi-spectral fluorescent imaging was extensively used to investigate the 
in vivo kinetics of labeled T-lymphocytes. In addition, the feasibility of indirect reporter gene 
imaging, using the (HSV1tk / [ 
124
I ] FIAU system) was also examined for PET imaging 
approach. 
 
 
 
 
 
 
51 
 
Chapter Four: Materials and Methods 
The following diagram is a summary of the project strategy, details are provided on the following 
pages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Harvesting, 
activating and ex 
vivo expansion of 
T-lymphocytes 
Direct labeling of 
expanded T-cells 
using NIR 
fluorescent probe 
for optical imaging  
In vitro evaluation of 
the labeling effect on 
cell proliferation, 
function, and viability 
 Multi-Spectral 
Fluorescent imaging at 
different time points 
Post-administration of 
labeled cells 
Indirect labeling using 
reporter gene HSV 
1tk- 
124
I-FIAU for 
PET imaging 
Transient transfection for 
optimization. 
Then stable transduction 
using lentiviral method 
In vitro detection 
of reporter gene 
expression  
Synthesis of 
radiolabeled 
[
124
I]-FIAU 
In vitro evaluation of  
[
124
I]-FIAU accumulation 
in the labeled cells 
Ex vivo 
growing 4T1 
Breast 
carcinoma 
tumor cells 
 PET imaging and 
biodistribution study 
at various time points 
 Post-administration of 
labeled cells 
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 4.1. Animals  
Female BALB/c mice, aged between 8-12 weeks, obtained from National Cancer Institute, 
Bethesda, MD, were caged in groups of five or fewer, and provided with food and water ad 
libitum. All animal experiments were performed according to the policies and guidelines of the 
Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University, 
USA.   
 
4.2. Cell lines 
Murine mammary breast carcinoma (4T1) cell line was kindly provided by Dr. Jane Tsai, 
Michigan Cancer Foundation, Detroit, Michigan. 4T1 cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal calf serum (Hyclone, Logan, 
UT) 1 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma, St. Louis MO) 
and 10 mM HEPES (Thermo Scientific). Tumor cells were trypsinized with 0.05% trypsin-EDTA 
(Fisher, Pittsburgh), washed with PBS and used for experiments. 
Meth-A sarcoma cells were obtained from American Type Culture Collection (Rockville, MD) 
and grown in DMEM media, containing 10% heat inactivated fetal bovine serum, 1 mM sodium 
pyruvate, 100 u/ml pen/strep, 10 mM HEPES, and 2 mM L-glutamine in incubator with 5% CO2, 
at 37° C. Cells > 90% confluence were trypsinized and used for experiments. 
Jurkat cell line was obtained from ATCC and grown in RPMI media, containg 10% heat 
inactivated fetal bovine serum, 100 u/ml pen/strep and were grown in the incubator  with 5% 
CO2, at 37° C. cells were counted every other day and kept at a concentration of one million per 
ml. 
53 
 
HEK 293 cell line was obtained from ATCC and grown in EMEM media containg 10% heat 
inactivated fetal bovine serum, 100 u/ml pen/strep and in the incubator  with 5% CO2, at 37° C. 
Cells > 90% confluence were trypsinized and split to be used for experiments. 
 
 4.3. Isolation, activation and in vitro expansion of 4T1 tumor specific T lymphocytes 
Donor mice were vaccinated in the left hind footpad with viable 1/2 x10
6
 4T1 cells. Ten days 
later, when these mice had a growing tumor in the foot, popliteal draining lymph nodes (DLN) 
were harvested under sterile conditions and disrupted through mesh screens to yield single cell 
suspensions. The cells from DLN were filtered and resuspended in complete RPMI media at 
1x10
6
 cell/ml concentration. These cells were then activated by incubating them with 5nM 
Bryostatin 1 (Sigma, St. Louis MO), 1µM Ionomycin (Calbiochem, San Diego, CA) and 80 U/ml 
IL-2 (Chiron, Emeryville, CA) at 37° C for 18 hours. To expand the lymphocyte population, cells 
were washed three times with warm, complete RPMI and resuspended at 1x10
6
 cells/ml 
concentration and divided into 2 groups: group-1 was incubated with 40 U/ml of IL-2 (IL2 cells) 
and group-2 incubated with IL7+ IL15 (10 ng/ml each) (Chiron, Emeryville, CA)  (IL7/15 cells)  . 
The cells were then allowed to proliferate in culture for 6-13 days and were split every other day 
to maintain 1-2x10
6
 cells/ml concentration. Fresh IL-2 or IL-7 +IL-15 was added at each split. 
Cell proliferation was calculated by determining the number of viable cells, on every other day of 
culture, by trypan blue exclusion and comparing it with the number of cells on day 1 of 
expansion. Luminescence based cell viability assays were also carried out as described below. 
 
  
 
54 
 
4.4. Labeling methods of T- lymphocytes  
T lymphocytes were labeled using two approaches: a) direct labeling using NIR fluorescent probe 
(DiR dye) for optical imaging, b) indirect labeling using the PET reporter gene (PRG) strategy 
(HSV1 tk RG) for PET imaging.   The direct labeling method was used to obtain some 
information about the in vivo trafficking of 4T1 sensitized T lymphocytes and to optimize our 
experimental model. The indirect labeling method was used to demonstrate its feasibility because 
it allows cell monitoring for long periods of time and it can be translated to the clinical setting. 
 
4.4.1 Direct labeling with NIR-fluorescent probe 
Direct labeling of T- lymphocytes isolated on day-6 after in vitro expansion was achieved by 
incubating the cells with 1,1-dioctadecyltetramethyl indotricarbocyanine Iodide (DiIC18(7) or 
DiR), a lipophilic Near-Infra red fluorescent dye (Absorption/ Emission: 748/780nm) 
(PerkinElmer, MA). DiR  (scheme 1) allows labeling the cell membrane through the insertion of 
the long 18-carbon chains into the cell membrane, resulting in specific and stable cell labeling 
with negligible dye transfer between cells .DiR stock solution was prepared by dissolving 25mg 
dye in 3ml Ethanol.  From this stock, further dilutions were made to the required concentrations 
in media and incubated with cells for 30 minutes at 37 
0
C (cells were shaken every 10- minutes). 
After incubation, cells were spun down at 1000 rpm at 4° C for 10 minutes, then washed twice 
with PBS and used for experiments.  
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.  
Scheme 1 the chemical structure of the fluorescent probe (DiR) 
To examine cell proliferation, viability and function before and after DiR labeling the following 
assays were performed:  
4.4.1.1. Cell proliferation assessment  
Cells were counted every other day using 0.4% Trypan blue (Mediatech VA)  and the number of 
viable cells was compared to their number immediately after pulsing with B/I. The result of this 
comparison is expressed as fold increase. Cell proliferation was assessed based on fold increase in 
cell number. 
 4.4.1.2. Cell Viability assays 
The highest tolerable concentration of DiR in the staining solution, which can be used to label T-
cells, was determined using Cell Titer-Glo Luminescent assay kit (Promega) and flow cytometry. 
Tumor sensitized lymphocytes, cultured in media  for 6 days in IL-2 or IL-7+IL-15 containing 
media, were labeled with a staining solution containing various concentrations (3.5, 14, 56, 224 
and 320 µg/ml) of DiR. Following labeling, 25000 cells/100 µl were plated in triplicates in a 96 
well plates, and incubated along with similar number of unlabeled cells in a 37° C CO2 incubator. 
After 1, 4 or 7 days of incubation, the Cell Titer Glo reagent was added to the cells and the % 
Viability was calculated for each labeled group in comparison to unlabeled cells (100% viability). 
For flow cytometry, DiR labeled and unlabeled T-cells (2 or 7 days post labeling) were double 
stained with propidium iodide (PI) and AnnexinV-FITC (BD Biosciences Pharmingen, San 
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Diego, CA) and analyzed using Beckman Coulter Epics XL-MCL flowcytometer and the data 
were analyzed using EXPO 32 software. Two different sets of experiments were performed to 
verify the results.  
4.4.1.3 Cell function assessment (Interferon- γ release assay)  
In vitro: Interferon-γ (IFN-γ) released into supernatants of 4T1 sensitized and expanded T-
lymphocytes in response to stimulation with irradiated 4T1 and Meth-A cells (non-specific 
control) was assayed using BD OptEIA mouse IFN-γ ELISA kit (BD Biosciences, San Jose, CA). 
T-cells obtained from popliteal DLN, which had been activated and expanded in either IL-2 or IL-
7 and IL-15 containing media, were collected on day 6 and incubated with DiR staining solution 
(320 µg/ml) . The DiR labeled and unlabeled cells were collected 1 day and 7 days post-labeling 
and incubated with the irradiated 4T1 or Meth-A tumor cells for 24 hrs, and the amount of IFN-γ 
in the supernatant was analyzed. As a negative control, 4T1 sensitized T cells alone were 
incubated under similar conditions.  
In vivo:  Blood was collected from three different groups of animals bearing: i) 10 day old 4T1 
tumor, ii) 10 day old 4T1 tumor and injected with 10 million labeled T-cells /mouse, iii) 10 day 
old Meth-A tumor and injected with similar number of activated and labeled T-cells. One week 
later, blood was collected and the amount of interferon-γ in serum was determined using the same 
kit and assay described above.  
 4.4.1.4. Animal model and T lymphocyte trafficking  
For the development of tumor models, mice were inoculated subcutaneously into the right flank 
with either 4T1 cells or Meth-A tumor cells (5x10
4
) and the tumor was allowed to grow for 3 days 
(average tumor volume size 20±5.6 mm
3
) or 7 days (average tumor volume size 80±10.3 mm
3
)  . 
To follow in vivo trafficking of T cells, 4T1 sensitized T-cells were first labeled with DiR 
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(320µg/ml staining solution). The cells were then filtered through 70-µm nylon mesh strainer and 
injected intravenously (iv) into the mouse tail vein (10x10
6
 cells in 0.5 ml PBS per mouse) either 
a week before or after the tumor cells were injected.  
To confirm that the detected signal at the tumor site is associated to the DiR labeled viable T 
cells, two experiments were performed. First: the DiR at same concentration as used for labeling 
was diluted in PBS and injected intravenously into 3 animals bearing 4T1 tumor. After 
fluorescent imaging at 2, 24 and 48 hours, animals were dissected and the ex vivo data were 
collected. Second: DiR labeled T cells were resuspended in PBS and lysed by freezing and 
thawing protocol for 6 times to ensure full cell lysate. Cell viability was tested using Trypan blue 
(0.4%).  The cell lysate was injected (tail vein i.v. injections) into 6 animals bearing 10 day 4T1 
tumors (3 for IL-2 cells and 3 for IL-7/15 cells). Fluorescent imaging was carried out for 2 weeks. 
One day before injection of DiR labeled T-lymphocytes, mice were pretreated, intraperitoneally 
(ip), with 100mg/kg Cyclophosphamide (CYP) (Mead Johnson, Princeton, NJ).  
4.4.1.5. Multi-spectral fluorescence imaging  
Fluorescent images were taken from day 1 to day 21 to monitor the homing and localization of 
labeled T lymphocytes at the tumor site. Multi-spectral fluorescence imaging system (Maestro-2 
by PerkinElmer, USA) was used to monitor DiR labeled T-lymphocyte trafficking and 
localization in host mice with and without tumors. A NIR/Orange double filter setup (640nm to 
820nm) and spectral unmixing was used for image acquisition and processing. Image processing 
and data analysis were performed using Maestro-2 software version 2.10. Images were  obtained 
at different time points ( 2 hours, 24 hours, 48 hours, 72 hours, 6-days , 8-days, 10-days, 13-days, 
15-days, 17-days, 20-days, and 21-days ) post-injection of labeled T-lymphocytes. Six mice per 
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time point were used; and four imaging positions, Dorsal, Ventral, Left and Right sides, were 
used at each time point. 
4.4.1.6. Immunohistochemistry analysis 
After imaging, mice were euthanized, organs and tumors were collected, embedded with Optimal 
Cutting Temperature compound (O.C.T, Tissue-Tek, USA) and stored at -80° C.  Using a cryostat 
system (LEICA CM1850 UV), five-micron thick serial sections of the samples were collected 
onto glass slides. The sections were fixed for 15 min in 3% freshly prepared paraformaldehyde in 
PBS (pH 7.4) at room temperature, and then washed three times with 0.3M glycine in PBS. 
Antigen retrieval was done using heat and citric acid buffer method. Following this, sections were 
washed three times in PBS for 5 min each, then incubated with blocking buffer ( 5% normal goat 
serum + 0.1% Triton X-100 in PBS, pH 7.4) for 1 hour at room temperature. Tissue sections were 
incubated overnight, at 4°C with Anti-F4/80 and Anti-CD69 primary antibodies (Abcam, USA).  
This was followed by incubation, for 1hr at room temperature, with Alexa Fluor 488 goat anti-rat 
IgG and Alexa Fluor 568 Goat anti-hamster IgG (Abcam, USA), which were used to detect 
macrophages and activated T cells respectively. The sections were cover-slipped with Vectashield 
Mounting Medium (Vector Laboratories, Burlingame, CA), and were then imaged and analyzed 
using Zeiss LSM 700 confocal laser scanning microscope.  
4.4.2. Indirect labeling method using PET Reporter Gene (PRG)  
 The second method was the indirect labeling of T- lymphocytes through transduction of reporter 
gene (cell cytoplasm labeling Herpes Simplex Virus type 1- thymidine kinase (HSV-1 tk). The 
product of this reporter gene is an enzyme that phosphorylates a radio labeled substrate  2-fluoro-
2-deoxy-1 β- D- arabinofuranosyl-5- 124I  iodouracil [ 124I ] FIAU  for PET imaging.  Before we 
established this method, we performed transient transfection using transfection reagents to 
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transfect Jurkat cells (these cells are T cells derived from a subject who had lymphoma; they are 
similar in their features to T cells and produce IL-2). The transient transfection method, as 
described below, was done to optimize our detection method (western blot) of the HSV1 tk 
expression. 
4.4.2.1. Transient transfection 
 4.4.2.1.1. HSV1tk vector isolation: 
An expression vector containing the HSV-1 tk fusion gene (pORF9-HSV-1tk: Sh ble) 
(Invitrogen) was transformed to E.coli bacteria strain GT116. The E coli bacteria was grown by 
streaking of 50µl of the E coli stock on LB agar plates and incubated for 24 hours at 37 
0
C. One 
single colony was picked up and grown in 10 ml of the LB media overnight at 37 
0
C. Then the 10 
ml Ecoli grown media was added to 150 ml of the LB media to grow overnight at 37 
0
C. The 150 
ml volume of the Ecoli grown media was enough to isolate good concentration of the plasmid 
vector.   The plasmid vector was isolated by Gen Elute HP- plasmid maxiprep kit ( Sigma- 
Alridsh) following the kit protocol.   The HSV1tk plasmid (DNA) concentration and purity was 
measured as following: 
The HSV1-tk plasmid concentration was calculated using the following formula: 
 Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50µg/ml 
A260   and A320  are the DNA and RNA absorbance respectively, measured by spectrophotometer, 
dilution factor = 100, the formula multiplied by 50µg/ml  because as role of thumb OD of 1 = 
50µg/ml. 
Total yield is obtained by multiplying the DNA concentration by the final total purified sample 
volume. 
DNA yield (µg) = DNA concentration × total sample volume (ml) 
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DNA purity was calculated using the following formula:  
DNA purity (A260/A280) = (A260 reading – A320 reading) ÷ (A280 reading – A320 reading) 
A280 = other contaminants absorbance. 
Good-quality DNA will have an A260/A280 ratio of 1.7–2.0. In our experiments we frequently have 
obtained DNA concentration between 500 to 700 µg/ml and DNA ratio of 1.7 -1.8. 
4.4.2.1.2. Confirmation of the presence of HSV1-tk gene in the isolated vector 
Using restriction enzymes (NcoI-HF and NheI-HF) (Invitrogen) to perform single and double cut 
of the HSV1-tk plasmid and perform gel electrophoresis to determine the plasmid size and 
confirm the presence of HSV1tk gene. The DNA resulted from maxiprep was  heated at 75
0
 C for 
10 minutes to inactivate DNase. Then 5 samples were prepared: sample 1 and sample 5 is 2ul 1Kb 
DNA ladder + 2ul gel loading dye to help as guide to calculated DNA size. Sample 2 is 2.5ul 
intact plasmid DNA + 2ul gel loading dye, sample 3 is single cut of DNA by Nco-I digestion 
enzyme ( 7ul + 2ul loading dye), sample 4 is double cut of DNA by Nco-I and Nhe-I digestion 
enzymes ( 10ul + 2ul loading dye).  
Sample 3 (single cut of DNA) preparations was done as following:  
 11.5ul dH2O+ 2ul 10X NE buffer+ 0.5ul Nco-I enzyme+ 6ul DNA.  
Sample 4 (double cut of DNA) preparations was done as following:  
10ul dH2O+ 2ul 10X NE buffer + 1ul BSA + 0.5ul Nco-I + 0.5ul Nhe-I + 6ul DNA. 
 Preparation of 1% Agarose gel was done as following: 
o.6gm of Agarose  powder + 60ml of 1X TAE buffer heated in the microwave then left to be 
cooled, 3ul Ethidium bromide was added then poured in the gel casting tray. 
 After all samples were loaded the gel electrophoresis was ran at 90V for one hour then imaged 
using UV Versa Doc imaging system. 
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4.4.2.1.3. Transfection of Jurkat cells using polymer-based transfection reagent 
Fugene-HD a polymer-based transfection reagent (Promega), was used to transfect Jurkat cells. 
Fugene-HD is a mixture of lipids and other components in 80% Ethanol. It does not require any 
ingredients of human or animal origin and also does not require removal of serum but using of 
antibiotics (AB) in the transfection medium is not recommended. DNA concentration has to be 
between 200µg/ml and 1mg/ml, its purity ( A260 / A280  ) has to be 1.7-1.9. The transfection 
procedure was done as following: 
 Cells were plated in 96 well plate 20,000/100µl media+ serum but no AB. DNA ( at 
concentration of 489 µg/ml and purity of 1.9) was diluted in 100µl free serum media then  Fugene 
transfection reagent was added to the diluted DNA at ratio of 6:1 (Fugene :DNA). (e.g. 2µg of 
DNA and 6µl of Fugene).  The mixture was incubated at room temperature (RT) for 10 minutes. 
Cells transfection was done by adding 5 µl of this mixture to each well of the 96 well plate and 
mixing gently by pipetting up and down 4 to 5 times. The plate was incubated at 37 
0
C for 24, 48, 
72 and 96 hours, and cells were collected and cell lysate was prepared for total protein 
calculations and Western blot to detect HSV1-tk expression.  
4.4.2.1.4. Cell lysate preparation 
Cells were counted and rinsed with cold PBS twice. (Washing and centrifuging). The final cell 
pellet was prepared without any remaining phosphate buffer saline (PBS) (Thermo Scientific). 
Lysis buffer was prepared by using RIPA lysate buffer (Thermo Scientific) 100 µl for each one 
million cells containing 1µl Halt complete protease inhibitor and µl EDTA (Thermo Scientific). 
Lysis buffer solution was added to the cell pellet, mixed by pipetting up and down many times 
then incubated in ice at RT for 30 minutes. Then the mixture was spun at 3000 rpm for 10 
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minutes at 4
0
 C. The supernatant was aliquated and stored at -80 
0
C for the following 
experiments.  
4.4.2.1.5. Protein concentration determination in cell lysate 
Protein assay kit (Pierce BCA ) ( Thermo Scientific) was used to determine the total protein 
concentration in the cell lysate. Serial dilution of the bovine serum albumin (BSA) stock (2 
µg/ml) in the RIPA lysis buffer (Thermo Scientific) was prepared as in table-1. 
Table 4 Serial dilution of BSA in RIPA lysis buffer 
 BCA stock µl 
Diluent µl (RIPA 
buffer) Concentration(µg/ml) 
A 200 - 2000 
B 90 from A 30 1500 
C 60 from A 60 1000 
D 60 from B 60 750 
E 60 from C 60 500 
F 60 from E 60 250 
G 60 from F 60 125 
H 56 from G 14 25 
I - 100 Blank 
 
In eppendorf tubes all of the standard samples from A to I as on the table were prepared first. 
Then in 96 well plate 10µl from A to I and 10 µl from our samples were put in duplicate. 200µl of 
working reagent (mixing of BCA reagent A and reagent B at ratio 50:1) was added to each well. 
The plate was put in the incubator, shaken for 30 sec then incubated without shaking for 30 min at 
37
0  
C. The samples were allowed to cool at RT for 5 min then were read at 595nm in the plate 
reader and spectrophotometer to compare both measurements.  The average OD of A to H was 
used to make the standard curve and calculate total protein concentration in each sample. 
4.4.2.1.6. Determination of the HSV1tk expression by Western blot 
All samples were put at 100
0 
C for 5 min in the water path., for protein denaturation to expose 
more epitopes (polypeptide fragment of the protein) to the primary antibody. 
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A mixture of Laemmle’s sample buffer (Gen DEPOT) and plus one Mercaptoethanol (GE Health 
Care - Biosciences) at ratio of 100:1 was prepared then added to samples at ratio of 4:1. Samples  
were loaded in 10% poly acrylamide gel , then the gel was run for 90 minutes at 120V in the 
running buffer (25mM Tris base ( Trizma) 4.53gm, 192 mM glycine 21.6gm, 7.5ml of % 20 SDS 
solution and distilled water was add to total volume of 1.5 L) . Two molecular weight markers 
were used: a) 2 µl of Xpert 2 Prestained protein marker (Gen Depot ) was used as rainbow marker 
to confirm the transfer process, b) 2µl of Odyssey molecular weight marker (Li-Cor) was used for 
quantification. The gel was transferred to PVDF membrane ( Immobilon transfer membranes- 
Millipore)  at 4 
0
C for 1 hour at 100 V in the transferring buffer (25mM Tris base ( Trizma) 
4.53gm, 192 mM glycine 21.6gm, methanol 300ml and distilled water was added to total volume 
of 1.5 L).  Transfer buffer was Stored at 4
0 
 C for 30 to 60 minutes.  Before the transfer process 
the PVDF membrane was wet in methanol for 1-2 minutes then in cold transfer buffer for 5 
minutes. The gel was equilibrated for 3-5 minutes in the cold transfer buffer before transferring. 
The membrane was blocked using 10 ml of block buffer (Odyssey buffer Li-Cor ) in the shaker at 
low speed at RT for 1 hour. Thymidine Kinase HSV-1 TK primary antibody (Santa Cruz 
Biotechnology) and Beta Actin mouse mAB primary antibody (cell signaling) were diluted with 
10 ml of Odyssey buffer and 20 µl of Tween 20 (Promega) at concentration of 1:10000.  The 
membrane was incubated with the diluted primary antibodies overnight on the shaker at low 
speed at 4 
0
C. On the second day the membrane was washed four times with washing buffer (50 
ml PBS + 50µl of Tween20) each time10 ml of the washing solution was added to the membrane 
and put on the shaker at medium speed for 10 minutes. Secondary antibodies against HSV-1TK 
(Donkey anti-Goat IRDye 680) (Li-Cor USA), and against beta-Actin (Donkey anti-Mouse 
IRDye 800 CW (Li-Cor) were diluted at concentration of 1:10000. The membrane was incubated 
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in the diluted secondary antibodies at RT on the shaker at low speed for 1 hour. The membrane 
was washed exactly as previous step after primary antibody incubation. Then the membrane was 
ready for imaging using Odyssey LX imaging system (Li-Cor). 
4.4.2.2. Stable transduction of Jurkat, HEK 293, 4T1 and T cells using HSV1tk lentiviral 
vector 
To be able to image T cells for long periods of time, stable transduction using Vira Power 
Lentiviral expression system (Invitrogen) was performed as follows: 
An expression vector containing HSV-1 tk fusion gene pMOD-HSV1tk (Invitrogen) was 
transformed to an E.coli bacteria strain GT100. The E coli bacteria was grown and the HSV1tk 
plasmid extraction, concentration and purification was performed using same methods described 
with the expression vector containing the HSV-1 tk fusion gene (pORF9-HSV-1tk: Sh ble). 
 To confirm the presence of  HSV1tk gene, the pMOD-HSV1tk  plasimed vector was cut ( single 
and double cut ) using restriction enzymes (NcoI-HF and NheI-HF) then Gel electrophoresis 
experiment was performed as described for the pORF9-HSV-1tk: Sh ble plasmid.  
To ensure that the pMOD-HSV1tk Ecoli is expressing HSV1TK protein, the Ecoli was grown and 
the optical density (OD) of 1.5 ml extraction of the E coli culture was measured using 
spectrophotometer (Beckman Coulter DU 730) at wavelength of 600 nm. The reading was 2.2 (it 
should be between 1.5 and 3.5). The bacterial cells were spun at 5000 rpm at 4 
0
C for 10 minutes. 
Then cells were resuspended in 300 µl of the lysis buffer ( 25 mM TrisHCLpH=8, 0.1 M NaCl, 
10% glycerol, 0.1 % Triton X-100 and 1mM PMSF) and vigorous overtaxing until the suspension 
is homogenous. The bacterial lysate was spun at 13000 rpm at 4 
0
C for 5 minutes to separate 
soluble proteins from insoluble proteins in the pellet. The supernatant was collected and stored at 
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– 80 0C for Protein assay and western blot assay. Both of these assays were performed as 
explained previously. 
4.4.2.2.1. Purification of HSV1TK protein 
 Once the expression of HSV1tk was confirmed in the Western blot result, the HSV1TK protein 
was purified from pMOD-HSV1tk Ecoli to be used as positive control for the following western 
blots. The HSV 1-TK Protein purification was done as follows: 
BL21/de3 E. coli were transformed with the pet21dTK plasmid and a stock of the transformant 
was made and stored at –80 C. The bacteria were grown in LB medium at 37 C until the A600 = 
0.5, then transferred to 18C, and when cooled 100 mg/l IPTG was added.  The growth was 
continued at 18 C for 18 hours, and then the bacteria harvested by centrifugation. Bacteria were 
disrupted by a single pass through an Avestin emulsiflex operating at a pressure of 25000 psi, and 
the lysate was clarified by centrifugation at 25000 rpm in and SW28 rotor for 30 min. The 
histidine tagged TK was purified by chromatography on a nickel –NTA agarose column as 
follows.  The lysate was added to the column, and then the column was washed extensively with 
25 mM tris, 300 mM NaCl, 10 mM imidazole until no 280 nm absorbing material eluted.  The 
bound protein was then eluted with 100 mM imidazole in the same buffer.  Fractions containing 
A280 absorbing material were checked by SDS gel electrophoresis.  The protein containing 
fractions were pooled, concentrated to 4 ml by ultrafiltration.  The material was then 
chromatographed on a sephacryl S200 column.  The fractions were monitored by SDS gel 
electrophoresis and TK containing peak fractions were pooled. Molecular weight =   40856.39 
about 41 KD, Residues = 374, Average Residue Weight = 109.242     Charged = 1, Isoelectric 
point = 8.00, Extinction coefficient = 38240 Therefore 1 mg/ml = A280 = 0.93 
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4.4.2.2.2. HSV1tk Lentivirus construction 
The pMOD-HSV1tk vector was cloned to pLenti6/UbC/V5/DEST (Lentiviral vector containing) 
following the Vira Power system protocol.  After the generation of the expression vector 
containing HSV1-tk (pLenti6-UBC-V5-DEST/pDONR221/HSV1tk). This vector was 
cotransfected to the  293FT cell line along with the packaging mix vectors ( pLP1, pLP2, and 
pLP/ VSVG required to produce the lentivirus). The cotransfection was done using Lipofectamine 
2000 transfection reagent based on cationic lipid-based formulation suitable for the transfection of 
this cell line with high efficiency.  The 293 FT cell line is a very suitable host for lentivirus 
production. Then the viral supernatant was collected and titrated to be used for stable 
transduction. Virus tittering was done following the Lenti-X GoStix kit (Invitroge). The final 
virus concentration is 9.2 x 10
5 
IU/µl.  The production and tittering  of HSV1tk lentivirus, was 
made at the VCU Macromolecule Core Facility, supported, in part, with the funding from NIH-
NCI Cancer Center Core Grant 5P30CA016059-29 
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Expression Clone/pLenti6-UBC-V5-DEST/pDONR221/HSV1tk
8795 bp
HSV1tk
attB1
attB2
Kpn I (1012)
Kpn I (7582)
Kpn I (8185)
Plasmid map of pMOD-
HSV1tk  
Lentiviral plasmid  map in 
which the HSV1tk was 
cloned to.  
The final vector after 
cloning which was used 
for Lentivirus construction 
Figure 8 the pMOD-HSV1tk was cloned to pLenti6/UbC/V5/DEST and the result is pLenti6-UBC-V5-
DEST/pDONR221/HSV1tk (HSV1tk-Lentiviral vector). 
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4.4.2.2.3. Creating stable transduced cell line 
HSV1tk-Lentiviral vector contains Blasticidin resistant gene instead of GFP as a selection marker.  
Therefore a stable transduced cell line was created before T lymphocytes were transduced. Three 
cell lines were used: Jurkat, HEK 293, and 4T1 breast carcinoma tumor cell line. 
4.4.2.2.4. Transduction procedure 
Cells were plated at concentration of 9.2 x10
5
  in 2.5 ml of their complete media in 6 well plate in 
duplicate. The virus stock was diluted in Opti-EMM reduced serum medium (Invitrogen) (10 µl 
of the virus stock to 500µl of the media). The multiplicity of infection (MOI) defined as the ratio 
of virus particles to the cell number was equal to 10. Polybrene (Millipore) at concentration of 
8µg/ml was added just before the virus stock was added to cells. The diluted virus was added as 
500 µl/ well gently drop by drop and cells were incubated at 37 
0
C for 24 hours. Then cells were 
washed 3 times with their media was then incubated at 37 
0
C for 5 days to allow the HSV1tk gene 
expression. The cells were split every other day and kept at concentration of 1 x10
6
 /ml.  
4.4.2.2.5. Selection of stable transduced cells using Blasticidin 
As the pLenti6-UBC-V5-DEST/pDONR221/HSV1tk vector has a Blasticidin resistance gene, all 
transduced cells should be resistant to Blasticidin. Based on this, Blasticidin (Invitrogen) was 
used to select only stable transduced cells. To know the optimum concentration of Blasticidin that 
will kill all cells, different concentrations of Blasticidin (1, 2, 4, 6 and 8µg/ml) were added to cells 
(25 % confluent) in 6 well plate. Viability assay was performed every 3 days and fresh media 
with Blasticidin at the same concentration was added. Cells were incubated with Blasticidin for 
14 days. The optimum concentration for each cell line was determined. Then it was added on day 
5 post transduction to all cell lines and cells were incubated for 14 days. This experiment was 
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repeated 2 to 3 times to make sure all transduced cells were selected. The transduced cells were 
cultured for several weeks and some were frozen for following experiments 
4.4.2.2.6. Confirmation of the presence of HSV1tk in the stable transduced cells by RT-PCR 
To confirm the presence of the HSV1tk gene in the stably transduced cells, Real-Time 
quantitative polymerase chain reaction (RT-PCR) was performed. Total RNA was extracted from 
Jurkat, 4T1, and HEK cells (8 to 10 million of each) using Trizol reagent (Invitrogen). The 
extraction procedure followed the reagent protocol. Then the RNA was purified using RNeasy 
mini kit (Qiagen) following the kit protocol.  The RNA concentration and purity was measured 
using spectrophotometer. The purity in most of our experiments was 1.8. The RT-PCR 
experiments were performed using the ViiA 7 system (Life Technologies) and TaqMan One Step 
PCR Master Mix Reagents Kit (Applied Biosystems). All the samples were tested in triplicate 
under the conditions recommended by the fabricant. The cycling conditions were: 48 
0
C/30min; 
95 
0
C/10min; and 40 cycles of 95 
0
C/15sec and 60 
0
C/1min. HSV1 tk primers: forward: 
CTCATGGCATGGGCAAGAC, reverse: CTCCTAGCACTCTCCAGTAGGTCAT,  
probe: ACCACTCAACTGCTGGTGGCACTGG. Mouse beta actin was used as a housekeeping 
gene for normalization. Beta actin primers: forward: ACG GCC AGG TCA TCA CTA TTG, 
reverse: TCA CAC TTC ATG ATG GAA TTG AAT G. TaqMan probe: FAM- CCA GCC TTC 
CTT CTT GGG TAT GGA ATC CT – TAMRA 
Reactions were performed in the VCU Nucleic Acid Research Facilities. 
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4.4.2.2.7. Detection of the HSV1tk expression in the stably transduced cell lines by Western 
blot 
Transduced and untransduced cells (Jurkat, HEK and 4T1 ( 10 x 10
6 
 of each)) were lysed after 2 
rounds of selection period using Blasticidin post-transduction and the total protein concentration 
was calculated using a protein assay kit; then western blot was done using 300 µg of the total 
protein as explained previously. 
4.4.2.2.8. Radiosynthesis of [124I]-FIAU (synthesis, mechanism of trapping by cells and 
characterizations) 
[
124
I]-FIAU was synthesized as described previously [64] with some modifications as shown in 
Scheme 2. Briefly, 
124
I was produced on the IBA Molecular cyclotron using the 
124
Te(p,n)
124
I 
nuclear reaction on an enriched 
124
TeO2/Al2O3 solid target. The 2’-fluoro-2’-deoxy-1-β-D-
arabinofuranosyl-5-(tri-n-butyltin)-uracil (FTBSnAU) precursor (0.5 to 1 mg) was dissolved in 50 
µL methanol and added 1 to 15 mCi (100 µL 0.1 M NaOH), followed by the addition of a 100-µL 
mixture of 30% hydrogen peroxide/ acetic acid (1:3, v/v). Reaction mixture was sonicated for 20 
min at room temperature.  After confirmation by radio- Thin Layer Chromatography (radio-TLC) 
(BIOSCINCE AR-2000) and radio-High Performance Liquid Chromatography (radio-HPLC) 
(Waters 1525), aqueous saturated sodium metabisulfate (100 mL) was added to quench the 
reaction.  Then the reaction mixture was loaded onto a preconditioned (10mL water-ethanol-
water) tC18-1gm Sep-Pak cartridge system (Waters, Milford, MA). The tC18 cartridge system was 
eluted with water (5 mL), followed by methanol (3–4 mL) to isolate the 124I-FIAU. The methanol 
was evaporated and the 
124
I-FIAU was formulated in PBS for in-vitro and in-vivo study.  Final 
product was analyzed by Rado-TLC and Radio-HPLC by co-elution with FLT standard. The 
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radiolabeled product was isolated in 95% radiochemical yield, with radiochemical purities of 
97%. 
 
 
 
Scheme 2: Radiosynthesis of [124I] FIAU 
 
 
 
 
 
 
 
Scheme 3 Mechanism of [ 
124
I] FIAU trapping by cell. Viral Thymidine kinase enzyme (HSV-
1TK)  transfers a γ phosphate group from ATP to the 5’ hydroxyl group of pyrimidine 
deoxynucleosides. The lipophilic tracer diffuses into the cell and is phosphorylated by HSV1-TK 
enzyme activity, and trapped within the cell. 
 
 
Radio-TLC was performed using radio–thin-layer chromatography (silica gel plates [Sigma-
Aldrich, St. Louis, MO]; eluent, ethyl acetate/acetone/H2O, 14:8:1) as shown in Figure 9. 
 
HSV-1TK enzyme 
[ 
124
I ] FIAU free [
124
I ] FIAU trapped in the cell 
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Figure 9, Radio-TLC of [
124
I]-FIAU before purification (panel A) and Radio-TLC of [
124
I]-FIAU 
after purification (panel B). 
 
 
Radio-HPLC analysis: The [
124
I]-FIAU was analyzed by radio-HPLC using the following 
conditions: using column C-18 luna Phenomenex 5µ C18 150 x 4.6 mm, mobile phase 10% 
Ethanol in 0.05 Molar NaH
2
PO
4
 at flow rate 1 mL/min, UV 2254 nm. The radiochemical identity 
was confirmed by co-injections with non-radioactive standard FIAU compound (Figure 10), and 
gave the same retention time as [
124
I]-FIAU, = 8.6 min. 
 
 
A 
B 
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Figure 10, HPLC profile of [
124
F]-FIAU (panel A) spiked with standard cold FIAU (panel B). 
 
 
 
Figure 11, HPLC profile of [
124
F]-FIAU (A) before Sep-Pak purification, and after Sep-Pak 
purification (B). 
 
4.4.2.2.9. 
124
I- [FIAU] uptake by Jurkat, 4T1 and HEK cells 
Transduced and untransduced Jurkat cells were put in gamma counting tubes at a concentration of 
5x10
6 
/ 3 ml of media in triplicate. Transduced and untransduced HEK 293 and 4T1 cells were 
plated in 12 well plate at of 300 x10
5 
cells / 2 ml of media in triplicate. 
124
I- [FIAU] was added at 
concentration of 1µci/ml. Cells were incubated at 37 
0
C for different time points (1, 2, 4 and 18 
hours). After each time point cells were spun at 1500 rpm at 4 
0
C for 8 minutes and cell 
A 
B 
A 
B 
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supernatant was collected for counting. Cells were washed 3 times with PBS and all wash was 
collected for counting. 50µl of cold PBS was added to the cell pellets and 50 µl of the supernatant 
and the wash was taken for counting. The % of cell uptake was calculated as following: 
% uptake = (CPM of cell pellets)/ (CPM of sum of cell pellet, cell supernatant, cell wash) 
multiplied by 100 
4.4.2.2.10 T lymphocytes transduction 
 T lymphocytes were isolated, activated and expanded as described previously. After the 18 hours 
incubation with Bryostatin/Ionomycin (B/I) cells were washed three times with warm, complete 
RPMI and resuspended at 1–2 x 106 cells/ml with 40 U/ml of IL-2 or with IL-7 and IL-15 (10 
ng/ml each) for 48 hours . On day 3 post expansion, cells were transduced with HSV1tk 
Lentivirus at different MOIs (10, 5, 2, 1, 0.2 and 0.03) to determine the best MOI for our in vivo 
studies. Cells were then plated at 1x10
6
 cells /ml in 24 well plates. Polyberene (as transfection 
reagent used to increase the transduction efficiency) was added at 8µg/ml just before cells were 
plated. Cells were incubated 37 
0
C for 4 hours. Then cells were washed with  media 3 times and 
incubated at 37 
0
C for 6-7 days. Cells were resuspended and fresh media with fresh cytokines was 
added every other day and cells kept grown at concentration 1-2 x10
6
/ml.  
4.4.2.2.11. Detection of HSV1tk expression in transduced T lymphocytes 
To check if the T lymphocytes were successfully transduced or not, real time PCR and western 
blot were performed as follow: 
In order to determine the changes in the  expression level of HSV1tk with time, on days 1,3,5,and 
7 post transduction, transduced and untransduced IL-2 and IL-7/15 at were collected and counted  
and about 20 x 10
6
  of each were used for real time -PCR. The procedure was done as described 
previously. 
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The HSV1TK protein was detected using Western blot assay. Transduced and untransduced IL2 
and IL7/15 T cells (25 x 10
6
) were lysed and the total protein concentration was calculated using 
protein assay kit; then western blot was done using 300 µg of the total protein as explained 
previously. 
4.4.2.2.12. Transduced T lymphocytes proliferation and viability 
Cell proliferation was assessed based on cell number and fold increase calculation every other 
day. Fold increase was calculated as the ratio of cell number each other day compared to the cell 
number immediately after pulsing with B/I. 
The cell viability at different MOIs was assessed using Cell Titer Glo Luminescent assay kit at 
different time points post transduction. Transduced and untransduced cells were plated in 
triplicate 96 well plates at 25000cells/100µl of media. The kit reagents were mixed and added to 
cells according to the kit protocol then was read by the plate reader ( DTX 880 Multimode 
detector Beckman Coulter) at 580 nm. The % viability was calculated for each group in 
comparison to unlabeled cells and expressed as % of viability.  
4.4.2.2.13. Transduced T lymphocytes phenotyping  
To investigate whether there is any effect of the transduction on the T lymphocyte phenotype; T 
lymphocytes were stained and tested using flow cytometry. Four groups of T cells (IL2 
untransduced and transduced cells, and IL7/15 transduced and untransduced cells) were double 
stained with CD8 or CD4 /CD62L or CD8 or CD4/CD69 antibiotics. One million of cells for each 
group was used in duplicate and stained with PECY5 anti mouse CD4 antibody, FITC anti mouse 
CD8 antibody, PE anti mouse CD69 antibody and PE anti mouse CD62L antibody (Bio Legend). 
The antibody concentration was 1µg/million of cells and FC (CD16/ CD32) block was used at the 
same concentration to remove any non-specific staining. Cells were resuspended in 2% FBS in 
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1X PBS and incubated with the antibodies for 30 minutes in a dark room, then spun and washed 
twice in 1X PBS with 2% FBS. Cells were tested using flow Cytometry to compare the 
percentages of CD8/CD69 and CD8/CD62L between transduced and untransduced cells. 
4.4.2.2.14 Interferon- γ production pre and post transduction 
To examine the interferon-γ production from T lymphocytes before and after transduction, the 
ELISA assay was performed. 4T1 tumor cells were irradiated using Gamma cell 40 Exactor 
system (10,000 rad for 30 to 60 minutes) to stop their proliferation. The irradiated cells were 
counted and brought to 1 x 10
6
 /ml. On day 6 post transduction, the transduced and untransduced 
T lymphocytes (grown in IL2 or IL7/15) were plated in 24 well plates at 2 x 10
6
 / 2 ml 
concentration.  The irradiated 4T1 cells (200µl) were added to each well (1:10 dilution) and 
incubated overnight at 37 
0
C. The interferon-γ (INF-γ) protein released into supernatants was 
collected and assayed using BD OptEIA mouse INF- γ ELISA kit (BD Biosciences, San Jose, 
CA). All samples were tested in duplicate and 8 groups were analyzed: 1) transduced IL2 T 
lymphocytes + 4T1 cells, 2) untransduced IL2 T lymphocytes + 4T1 cells, 3) Nil transduced IL2 
T lymphocytes, 4) Nil untransduced T lymphocytes, and similar 4 groups for IL7/15 T 
lymphocytes. (Nil stands for T cells incubated alone without irradiated 4T1 cells). 
4.4.2.2.15. 
124
I- [FIAU] uptake by T lymphocytes 
Transduced T cells (IL-2 and IL-7/15cells) and transduced Jurkat cells were put in gamma 
counting tubes at concentration of 5x10
6 
/3ml of their media in triplicate.   
124
I- [FIAU] was added 
at concentration of 1µCi/ml. Cells were incubated at 37 
0
C for different time points (1, 4 and 18 
hours). After each time point, cells were spun at 1500 rpm at 4 
0
C for 8 minutes and cells 
supernatant was collected for counting. Cells were washed 3 times with PBS and all wash was 
collected for counting. 50µl of cold Lysate buffer (RIPA lysate buffer) was added to the cells 
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pellets and 50 µl of the supernatant and the wash was taken for counting. The % of cell uptake 
was calculated as following: 
% of uptake = CPM of cell pellet/ CPM of sum of cell pellet, cell supernatant, cell wash 
multiplied by 100. 
4.4.2.2.16. Multi-labeled T lymphocytes trafficking and imaging (Optical & PET) 
Transduced and untransduced IL2 and IL7/15 T cells were labeled with DiR at 320µg/ml 
concentration as described previously. For development of tumor models, animals were 
inoculated subcutaneously into the right flank with 4T1 breast carcinoma tumor (5 x 10
4
) and 
allowed the tumor to grow for 10 days. One day before injection of labeled T cells, animals were 
pretreated (ip) with 100mg/kg Cyclophosphamide to reduce the number of T regulatory cells by 
increasing the number of effective CD8 and CD4 cells. The transduced and untransduced T cells 
were prepared (10 x10
6
 in 0.5 ml PBS per animal) and injected i.v. via tail vein into four groups 
of animals (IL2 transduced-6 animals, IL2 untransduced-3 animals, IL7/15 transduced-6 animals 
and IL7/15 untransduced-3 animals) were injected (tail vein injections) with 
124
I [FIAU] (activity 
between 300 to 500 µCi). Because the imaging time was carried out for two weeks and the half-
life of 
124
I is 3.8 days, the activity of 
124
I [FIAU] was injected in the first and second week of 
imaging. The multi-spectral fluorescence imaging was established as described previously.   
4.4.2.2.17. Biodistribution study 
In order to track and localize the transduced T cells post 
124
I [FIAU] injections into the four 
groups of animals, biodistribution study was carried out at different time points (day 3 and day 10 
post radionuclide injections).  Animals were dissected on day 3 post first radionuclide injections 
(3 animals from each transduced cells group) and the other 3 animals with the untransduced cells 
groups were dissected on day 10 of imaging and it was day 3 post the second injection. Most of 
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the animal tissues were collected and their activities in CPM were measured using Gamma 
counting system (1282 COMPUGAMMA CS universal Gamma counter). The % ID/g of each 
tissue was calculated using the following formula: 
% ID = 100 x tissue activity (µCi) / injected activity (µCi) x tissue mass (g) 
Tissue activity in µCi was calculated from tissue activity in CPM converted to dpm using 
efficiency factor as following: 
dpm = CPM / efficiency factor ,  1 µCi = 2.22 x 10
6 
dpm. 
Efficiency factor was calculated by measuring 4 different activities of [
124
I ] FIAU 
( 2.1399±0.7912, 2.7959±0.6867, 4.1044±0.5687 and 3.1908±0.6438) in µCi using Gamma 
Spectrophotometer system ( ORTEC-50 AMETEK) and same activities were measured in CPM 
by gamma counter. Then DPM was calculated by multiplying activities measured in µCi by 
2220000. The efficiency factor is CPM/DPM, which is 0.31 for 
124
I  in our measurements and was 
used for our Biodistribution study calculations. 
4.4.2.2.18. Detection of HSV1TK at some organs in vivo 
Some of the organs (liver, lungs, spleen, tumor and lymph nodes) were collected after animal 
dissection and immediately were snap frozen in liquid nitrogen. Protein assay and Western blots 
were performed as described previously to verify the localization of transduced T cell at these 
organs.  
4.5. Studying the trafficking pattern of T lymphocytes to 4T1 metastasis 
The final objective in this project was, to study the trafficking pattern of IL2 and IL7/15 T cells to 
4T1 tumor metastasis. 4T1 cells were successfully transduced with HSV1tk gene as verified by 
RT-PCR and western blot. Transduced 4T1 cells were implanted in the abdominal fat mammary 
pad of some of animals (orthotopic tumor) and others were implanted in the right flank of the 
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animal and untransduced 4T1 tumor was implanted in the left flank. PET imaging was performed 
on the third and fourth week post tumor implantation. Firefly-luciferase expressing T cells were 
provided kindly from Dr Bear’s lab and injected i.v. on the third week post 4T1 implantation into 
the abdominal fat mammary pad animals and bioluminescence imaging were performed for one 
week. Then animals were dissected and Western blot of some organs was performed. 
 
4.6. Statistical analysis  
The significant differences in the ex vivo and in vivo studies were determined using the equal 
variance analysis (ANOVA) (JMP software), or Student’s t-test. P value of < 0.05 was considered 
as statistically significant difference. The data shown in graphs are mean ± SEM. 
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Chapter Five: Results 
5.1. Direct labeling of T lymphocytes using DiR probe 
5.1.1. DiR signal detection and labeling efficiency  
To test how long the DiR signal is maintained after staining of cells, DiR labeled T lymphocytes 
were cultured and imaged at different time points. DiR labeled cells (0.5 or 1.0 x 10
6
 per well ) 
were washed and plated in 6 well plates at each and time point then imaged  up to 9 days.  The 
result showed good signal maintenance and detection for more than one week (Figure 12, panel 
A). The efficiency of DiR labeling of T cells was tested using flow Cytometry (Figure 12 panel 
B). The result showed that nearly 100% of cells were labeled. 
   
 
1.0x10
6 
    0.5x10
6
  
 
 A 
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Figure 12 DiR labeled T cells were imaged at different time points up to day 9 (Panel A). DiR 
labeled T cells showed detectable signal for more than one week. On days 7 and 9 only few cells 
were left, that’s why only half million of cells were plated. Even on day 9 the DiR signal looks 
stronger than previous days, because of the fluorescence quenching phenomenon. This means 
decrease of the fluorescence signal given from too much intense fluorescence material. In our 
case, as cells divided the DiR is diluted with each division and the DiR become more and more 
diluted (less intense) leading to prevent fluorescence quenching and increase DiR fluorescent 
signal. Panel B is flow cytometry data showed that the mean fluorescent intensity (MFI) is 
increasing with DiR labeled CD3 T cells and the labeling efficiency with DiR is 94 %.  
 
5.1.2. DiR labels T cells with negligible transfer to tumor cells 
DiR has two long 18- carbon chains that insert into the cell membrane, which showed specific and 
stable cell labeling with negligible transfer between cells. To test this property of DiR, T 
lymphocytes were labeled with DiR and incubated with 4T1 tumor cells for 24 hours in 6 well 
plates.  Then DiR labeled T cells were washed out from 4T1 cells wells (T cells are flouting cells 
and 4T1 are adherent cells). Multi-spectral fluorescent imaging system was used to image the 
plates (Figure 13). The DiR signal was clearly detected in the DiR T cell well, but not in the DiR 
 B 
T cells stained                               DiR labeled                                      DiR + CD3 
  for CD3                                             T cells                                           T cells 
MFI: 4,524 MFI: 3,899 
94.0% 
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T cells + 4T1 tumor cells well, indicating that, DiR specifically labeled T cells and did not 
transfer to 4T1 tumor cells.   
 
 
 
5.1.3. Cell proliferation pre and post labeling were comparable  
The proliferation of 4T1 sensitized T lymphocytes isolated from tumor DLN activated with B/I 
and expanded in IL-2 or IL-7 + IL-15 containing media was observed for 10 days. Since the 
number of T lymphocytes from day 6 was high (figure 14), these cells were labeled with DiR to 
be adoptively transferred into 4T1 tumor bearing mice, and the effect of labeling cells with DiR 
on proliferation was determined. The results confirmed that, cells labeled with DiR showed 
similar proliferation as the unlabeled T cells (Figure 14). Both unlabeled and labeled cells 
continue to proliferate at the same rate until day 4 post-labeling (day 10 of expansion). These 
results showed that labeling of cells with DiR does not affect the proliferation of the T 
lymphocytes grown in the presence of IL-2 or IL-7 + IL-15 even for 10 days of expansion.  
      DiR T cells         DiR T cells +4T1 cells       DiR T cells        DiR T cells +4T1 cells           
       Fluorescent imaging                     Post spectral un-mixing 
Figure 13 DiR labeled T cells incubated with 4T1 tumor cells for 24 hrs, showed 
negligible to no transfer between both cells. (Post Spectral un-mixing refers to auto 
fluorescence signal subtraction and show only DiR signal) 
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Figure 14 T cell proliferation based on viable cell counts on each day compared to the number of 
cells on day 1 of ex vivo expansion. Cell number was highest on day 6. Therefore, this was the 
chosen time for labeling. Furthermore, no significant differences between labeled and unlabeled 
cell proliferation post-labeling. (Fold increase in cell number is the number of cells at each day 
pre or post labeling compared to the cell number on day 1 directly after the activation in B/I) 
 
 
5.1.4. DiR labeled cells showed 80-90 % viability when labeled using 320µg/ml of labeling 
solution 
 
The viability of lymphocytes labeled with various concentrations of DiR was assessed to 
determine the optimum non-toxic concentration with which cells could be labeled. Since T cells 
which have been B/I activated and expanded in IL-2 or IL-7+IL-15 containing media for six days 
were used for in vivo studies, the viability of cells from day 6 onwards was monitored, when 
labeled with DiR and compared with unlabeled T cells. The results show that there were no 
significant differences in % viability among the various concentrations of DiR tested compared to 
unlabeled cells on days 1 and 4 post-labeling. However there is a significant difference (p < 0.05) 
in the viability of cells recovered on day 7 compared to viability tested at unlabeled cells and to 
days 1 and 4. Since on days 1 and 4 the cells were 80-90% viable even at the highest 
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concentration of DiR used (320 µg/ml), this concentration was used for further in vitro and in vivo 
studies (Figure 15 Panel A, Panel B)) as the higher amount of DiR on cell membranes is likely to 
allow signal retention and in vivo detection for relatively longer durations. 
Tumor sensitized lymphocytes were labeled with 320µg/ml of DiR and on day 2 and 7 post-
labeling, were incubated with Annexin V/PI to determine the cause of cell death. The flow 
cytometry results showed that, the cell viability of unlabeled and labeled cells was comparable 
(figure 16). As explained previously, cells grown in IL7/15 higher viability than cells grown in 
IL2 regarding of labeling. 
 
Figure 15 Percent viability of T cells labeled with various concentrations of DiR measured using 
Cell TiterGlo assay.  Bryostatin/Ionomycin (B/I) activated 4T1-cells grown in IL-2 were labeled 
on day 6 of their ex vivo expansion. Viability of T-cells 1, 4 and 7 days post-labeling was 
compared with unlabeled cells and expressed as percent viability. * and #  means there is a 
significant difference in the cell viability between day 1 to day 7 and day 4 to day 7 respectively. 
These differences were more observable with IL2 cells than IL7/15 cells. Cells showed 80 to 
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90 % viability on days 1 and 4 post-labeling and no significant differences compared to unlabeled 
cells. On day 7 post-labeling which is day-13 post-labeling, cell viability was 60% or below and 
showed significant differences compared to unlabeled cells because these are primary cells and 
their viability decreases beyond day 10 of ex vivo expansion. Average ±S.D from three different 
experiments are shown in the graph. 
 
 
 
 
 
 
 
 
 
                 
 
                                        
 
 
 
 
 
UN-labeled IL2 cells (% of viability = 39.5%)        Labeled IL2 cells (% of viability = 46.3%) 
Day 2 post DiR labeling 
PI 
PI 
Annexin V-FITC 
AnnexinV-FITC 
UN-labeled IL7/15 cells (% of viability = 85.2%)        Labeled IL7/15 cells (% of viability = 86.1%) 
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Figure 16 T cells % of viability tested by flow cytometry (apoptosis kit). DiR labeled cells were 
tested on days 2 and 7 post labeling. All results showed that, the viability of DiR labeled cells is 
somehow higher than unlabeled cells, indicating that, DiR probe does not affect cell viability. 
 
5.1.5. Interferon-γ production in vitro and in vivo  
In vitro activated 4T1 sensitized T cells were expanded for 6 days, and incubated (either 
unlabeled or DiR-labeled) with irradiated 4T1 tumor cells or MethA tumor cells for 24 hours in 
IL-2 or IL7/15 containing media. The levels of IFN-γ in the supernatant were determined. The 
results showed that, with time there is accumulation of IFN-γ in the media but there is no 
significant difference in the IFN-γ levels in the supernatant of T cells, incubated alone compared 
to T cells incubated with non-specific Meth A tumor (Figure 17 panels A & B) on respective 
days. However, T cells incubated with 4T1 tumor cells showed significantly higher release of 
UN-labeled IL2 cells (% of viability = 63.3%)        Labeled IL2 cells (% of viability = 76.4%) 
Annexin V-FITC 
PI 
Day 7 post labeling 
UN-labeled IL7/15 cells (% of viability = 78.7%)        Labeled IL7/15 cells (% of viability = 88.3%) 
Annexin V-FITC 
PI 
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IFN-γ into the media (p<0.05) than cells incubated alone (Nil cells) or with Meth A tumor. Since 
no significant differences in cytokine levels released were observed between unlabeled and 
labeled T cells, the data also demonstrate that labeling the cells with DiR does not affect their 
interaction with tumor cells. Figure 17 panel C shows that, the amount of IFN-γ in the mice 
bearing 4T1 tumor which have been injected with labeled T cells, is higher in their blood serum 
compared with mice bearing 4T1 tumor only (no T cells infused) and mice bearing Meth A and 
which have been injected with labeled T cells.  
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Figure 17 The amount of interferon-γ released in the cells supernatant and in vivo mice serum 
showed higher amount of this cytokine in both cases, when the 4T1 specific T cells or in the mice 
injected with 4T1 specific T-cells compared to other groups as shown in  panel A, B and C.  
 
5.1.6. Multi-spectral fluorescent imaging of T cell trafficking 
Adoptive transfer of DiR labeled 4T1 sensitized T lymphocytes which had been expanded 
in vitro for 6 days, were administrated intravenously 4 day or one week after tumor implantation. 
Imaging of the mice using Maestro-2, revealed homing of 4T1 sensitized lymphocytes to the site 
of 4T1 tumor. The signals from DiR labeled cells persisted in tumor bearing mice for up to 21 
days (Figure 18A). The tumor/Background ratio (Tumor/BKG Ratio ) shows that the peak signal 
intensity is obtained on day 6 after adoptive transfer, following which the signal intensity started 
to gradually diminish (Figure 18C). In contrast, when the 4T1 sensitized lymphocytes were 
injected into a Meth A tumor bearing mice, there was no migration of DiR labeled cells to the 
tumor site. This is indicated by lack of fluorescence signal obtained from the tumor site (Figure 
18, panel B). This suggests that these IL-2 grown T cells are antigen specific. For T cells grown in 
IL7/15, their signal was lower than IL2 cells signal and peaked on day 8 (figure 20). This may 
due to the IL7/15 in vivo proliferation at the tumor site. They proliferate more than IL2 cells, 
which may lead to the dilution of the labeling probe and reduced signal. 
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Day 1                 Day 3                Day 6             Day 15          Day 21 
 
Figure 18. Fluorescence imaging of T cell trafficking. Homing of 4T1 sensitized DiR labeled T 
cells to (Panel A) 4T1 tumor site (green color codes for Autofluorescence signal , and red color 
codes for DiR signal ), (Panel B) Meth-A carcinoma tumor site (used as negative control tumor) 4 
days after the tumors have been implanted. Red color indicates the signal from the NIR DiR Dye 
used to label the T cells. (C) Tumor/ Background ratios graph showed that, cells localized at the 
tumor site on day 1 peaked on day 6 and persisted up to 21 days in the animal. While in case of 
Meth A tumor, there was no localization of 4T1 specific T cells at the tumor site. 
 
To determine whether signals from DiR labeled 4T1 sensitized T cells can persist in vivo for a 
prolonged period of time, 4T1 tumor cells were introduced one week after the mice had already 
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received infusion of activated/expanded T cells. Interestingly, the T cells migrated to the site of 
tumor as early as 2 hours post injection of tumor cells and the signals from DiR tagged T cells 
were detectable for more than 2 weeks (Figure 19A). Further examination of the 
tumor/background (BKG) ratio revealed that the signal intensity had increased modestly on day 3 
and then began to gradually decline (Figure 19 B).   
 
 
Pre- 4T1 inoculation     {2 hrs           24 hrs            1 week         2 weeks} 
                              {Post 4T1 inoculation} 
  
 
Figure 19. Fluorescence imaging of T cell trafficking (A) Adoptive of 4T1 sensitized T cells 
expanded in IL-2 media, injected one week prior to 4T1 challenge. The labeled 4T1 specific T 
cells were able to leave the lymphoid compartment and localized at the tumor site in 2 hours. 
Green color denotes Autofluorescence and the Red color denotes the signal from DiR labeled 
lymphocytes. (B) Tumor/ Background ratios obtained from mice injected with T cells and 
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inoculated with 4T1 cells a week later. The graph showed the signal appeared on day 1 (on the 2 
hours image) peaked on day 3 and persisted 21 days in the mice. 
 
 
 
 
Figure 20 Tumor/ Background ratios graph of animals bearing 3 days 4T1 tumor and injected 
with IL7/15 cells. The graph showed that, cells localized at the tumor site on day 1, peaked on day 
8 then decreased sharply with time up to 21 days in the animal.  
 
To confirm that the signal that was detected at the tumor site  was linked to viable DiR labeled T 
cells, a cell lysate was injected in number of animals and imaged at different time points starting 
from day 1 to day 14.  No signal was detected at the tumor site or lymph nodes in the cell lysate 
group. However, there was signal detected in lung, spleen and liver because of the route of 
administration (i.v. injections of cell lysate). In contrast, after infusion of viable DiR labeled cells, 
tumor and lymph nodes showed detectable signal which increased with time, indicating that more 
T cells are migrated or proliferated at these sites.  
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Figure 21 Fluorescence imaging of IL2 cell trafficking. Homing of 4T1 sensitized DiR labeled 
cells to 4T1 tumor site 7 days after the tumors have been implanted (panel A), Panel B fluorescent 
imaging of animals injected with the IL2 cell lysate supernatant. Red color indicates the signal 
from the NIR DiR Dye used to label the T cells. (C) Tumor/ Background ratios graph showed 
that, cells localized at the tumor site on day 1(on 2hrs) peaked on day 3 and persisted up to 14 
days in the animal. While in case of IL2 lysate, there was no localization of 4T1 specific T cells at 
the tumor site. 
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Figure 22 Fluorescence imaging of IL7/15 cell trafficking. Homing of 4T1 sensitized DiR labeled  
cells to 4T1 tumor site 7 days after the tumors have been implanted (panel A), Panel B fluorescent 
imaging of animals injected with the IL7/15 cell lysate. Red color indicates the signal from the 
NIR  DiR Dye used to label the T cells. (C) Tumor/ Background ratios graph showed that, cells 
localized at the tumor site on day  peaked on day 3 and persisted up to 14 days in the animal. 
While in case of IL7/15 lysate , there was no localization of 4T1 specific T cells at the tumor site. 
 
 
5.1.7. Localization of labeled T-lymphocytes at tumor and non-tumor tissues 
To investigate the migration pattern of 4T1 sensitized T cells following inoculation to sites 
besides the tumor site, tumor bearing mice were dissected at various time points following 
inoculation with DiR labeled T cells and different organs were removed and imaged ex vivo. 
Besides tumor, labeled T lymphocytes were also seen to have localized to liver, spleen, lungs, 
lymph nodes and bone marrow, as shown in Figure 23 panels A, B,C and D. Figure 23 panels E 
and F show  signal to background ratio of labeled T-lymphocytes in these organs on days 3 and 
10 post-injection of labeled T cells. The signal increased modestly with time, which would 
indicate that additional labeled cells were migrating to these sites. 
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Figure 23 panels A,B,C and D Fluorescence imaging of tumor, liver, lungs, spleen, and 
bone marrow ex vivo. (E,F) Quantitation of the signal from labeled T-lymphocytes at the 
tumor site and other organs on days 3 and 10 post T-cells administration.  
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5.1.8. T cells specificity and their AIT function with or without DiR labeling in vivo 
 
        To test the specificity of T cells as antigen specific cells for 4T1 tumor with and without 
labeling with DiR and their immune function  in vivo, number of animals were classified into 8 
groups ( 6 animals in each), group 1 animals with 4T1only ( control 4T1) group 2 same as group 
1 for Meth A tumor (control meth A), group 3 animals with 4T1 injected with 
cychlophosphamide (CYP) only (CYP 4T1), group 4 same as 3 but for Meth A (CYP Meth A), 
group 5 animals injected with T cells and CYP ( CYP 4T1 AIT), group 6 same as group 5 but for 
Meth A (CYP Meth A AIT), group 7 and 8 same as groups 5 and 6 but T cells were labeled with 
DiR (CYP AIT 4T1 DiR) and ( CYP AIT Meth A DiR).   The tumors were implanted 
intradermally in the left flank, CYP was given on Day 3, and AIT (ex vivo activated T cells with 
and without labeling with DiR) on Day 4 after tumor implantation. Tumor volume was measured 
for about one month post treatment. Figure 24 showed the results of this experiment; two 
important observations are noticed; first T cells are antigen specific against 4T1 tumor and no 
activity was observed against Math A tumor. This result is consistent with our previous data 
shown in figure 18. Second, DiR does not show any effect on the T cells function in vivo after 
adoptive transfer. 
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Figure 24 T cells with and without DiR labeling function in vivo against 4T1 and Meth A tumors. 
Panel A T cells activity against 4T1 tumor, tumor volume was zero starting from day 6 after AIT 
(T cells with or without DiR labeling) administrations. Control and CYP groups showed an 
increase in the tumor volume as time increases. Panel B  T cells activity against Meth A tumor, no 
decrease or regression in the tumor volume with time and no differences compared to other 
groups (control and CYP), indicating that T cells are antigen specific against 4T1 tumor. 
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5.1.9. Immunohistochemistry confirms localization of activated T cells at the tumor site  
 
          To confirm the localization of the activated T-lymphocytes to the tumor site, 5 micron thick 
tumor sections from mice inoculated with DiR labeled T cells were stained for CD69 and F4/80 to 
detect activated T-lymphocytes and macrophages respectively. Both activated T lymphocytes and 
macrophages were visualized at the tumor site as shown in Figure 25. A, B, C and D are different 
sections of the tumor from outside to deep inside the tumor. The activated T lymphocytes were 
mostly localized at the superficial layer of the tumor; macrophages were localized deeper inside 
the tumor tissues. To ensure that the localization of macrophages at the tumor site was not to 
attack and engulf labeled activated T-lymphocytes, we implanted 4T1 breast carcinoma tumor in a 
number of mice and dissected them after 10 days when they have the same tumor size as in our 
previous experiments. These mice were not injected with activated T lymphocytes. Tumors were 
sectioned, double stained for CD69 and F4/80 and then imaged. Figure-25 E, F, G and H illustrate 
the images of these sections, and we did not see any activated T cells at these tumors and this was 
expected. Spleen sections were used as positive control for T-lymphocytes. Whereas, liver was 
used as positive control for macrophages, both spleen and liver images are demonstrated in 
Figure-25 E and F. 
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Figure 25 (A-B) Mouse bearing 4T1 tumor was injected with activated T-cells and the tumor 
sections were stained for CD69 activated T-cells (red color) marker and F4/80 macrophage (green 
color) marker. (C-D) Images of 4T1 tumor sections obtained from mouse bearing 4T1 tumor but 
not injected with activated T cells, stained for CD69 and F4/80 markers. (E) Spleen section 
stained for CD69 (used as positive control for activated T-cells) and (F) Liver section stained 
F4/80 (used as positive control of macrophages).  
 
5.1.10. Confirmation of immunehistochemistry results by flow cytometry  
To validate that adoptively transferred labeled T cells (AIT) are not engulfed by 
macrophages or the DiR is transferring to other immune cells, tissues (liver, spleen, bone marrow 
(BM) and tumor) that showed high accumulation of T cells were collected and digested on day 7 
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post AIT injections. Following tissues were also stained for macrophages (F4/80) and immune 
cell marker (CD45) for flow cytometry analysis. CD45 is expressed on almost all hematopoietic 
cells except for mature erythrocytes. We are testing if DiR is associated with any other cells than 
T cells, particularly macrophages and other hematopoietic cells. The result (figure 26) shows that 
no DiR was associated with F4/80 or CD45 indicating that, DiR is linked to T cells and did not 
transfer to other cells. 
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Figure 26 assessment of immunohistochemistry result by flow cytometry. Panel A tissues were 
stained for macrophages (F4/80), panel B tissues were stained for immune cell marker CD45. 
Both confirm that DiR is linked to T cells and no transfer of DiR to other cells. 
 
5.1.11. Verification of DiR labeled cells localization at tumor site 
To validate whether the DiR signal at the tumor site is connected to the DiR labeled cells, DiR 
stock was diluted and prepared in PBS as described previously and injected to number of animals 
bearing 4T1 tumor.  Fluorescent imaging was done at 3 time points (2, 24 and 48 hours post i.v. 
injection). The animals were dissected after 48 hours and organs were removed and sectioned. 
Figure 27 showed the fluorescent images of liver, heart and tumor sections. No signal was 
detected at the tumor section indicating that, the DiR signal at the tumor site connected to DiR 
labeled T cells. 
 
   
 
Figure 27 fluorescent images of liver, heart and 4T1 tumor sections of animal injected with DiR 
only. From the ex vivo imaging higher signal was detected in the liver and no signal was in the 
heart, that is why liver was used as positive and heart negative controls. 4T1 tumor section 
showed no signal of DiR indicating that, the signal detected at the tumor site is correlated to DiR 
labeled cells. 
 
5.2. Indirect labeling of T lymphocytes by PRG (HSV1tk) 
5.2.1. Transient  transfection by transfection reagent 
To optimize the HSV1tk gene expression detection, transient transfection was performed with 
Jurkat cells. pROF9-HSV1 tk-sh plasmid was isolated from GT116 Ecoli and was then cut to 
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single and double cuts using restriction enzymes to perform gel electrophoresis assay. The result 
shown (figure 28) confirmed the presence of HSV1tk gene in the Ecoli plasmid. According to the 
band size calculations in relation to the DNA ladder, bands 3 and 4 showed HSV1tk size exactly 
as shown in the plasmid map. 
 
 
Figure 28 Gel electrophoresis result (panel A) confirmed the presence of HSV1tk gene.1 and 5 
DNA ladder, 2= plasmid intact DNA move as coils can’t calculate its size, 3= single cut Using 
NcoI restriction enzyme (linearized plasmid) (first band= 4580bp), 4= double cut using 2 
restriction enzymes NcoI, and NheI (first band = 4580bp- (2148bp-561bp) = 2993bp)(Second 
band = 2148bp-561bp = 1587bp). Panel B showed pROF9-HSV1tk-sh plasmid map. 
 
The HSV1tk vector was used for transient transfection of Jurkat cells. Figure 29 shows the 
western blot result post transfection using polymer based transfection reagent (Fugene). Ecoli 
lysate was used as positive control for HSV1TK protein. Cells showed expression of the gene up 
to 4 days (the end of cell lysate collection). This experiment was done to optimize western blot 
protocol and make sure the primary antibody is specific for HSV1 TK enzyme. 
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Figure 29 western blot result of transfected jurkat cell exhibit HSV1 tk expression in jurkat cells 
at different time points post transfection. 
 
5.2.2. Stable transduction by HSV1tk lentivirus 
5.2.2.1. Confirmation of the presence of HSV1tk gene in pMOD-HSV1tk plasmid 
HSV1tk gene was transformed to pMOD-HSV1tk plasmid (GT100 Ecoli,) and then was extracted 
to be cloned to the lentiviral vector to construct HSV1tk lentivirus as described previously. Figure 
30 shows HSVtk plasmid map (panel B) and according to the calculations of the band sizes in the 
gel electrophoresis result (panel A), the HSV1tk gene is present in the pMOD-HSV1tk vector.  
To make sure the HSV1tk gene expresses HSV1TK enzyme, the Ecoli was lysed and western blot 
assay was performed as shown in figure 31.  HSV1TK enzyme bands are clearly observed at 7, 
10, 13 µg of the total protein of the Ecoli lysate. Based on this result this plasmid vector was 
chosen to construct the HSV1tk lentivirus. 
50 KD 
 
37 KD HSV1TK 
 41 KD 
Tranfected jurkat cells 
 expressing HSV1TK 
  24hrs    48hrs    72hrs   96hrs Un-Transfected  
          cells 
104 
 
 
Figure 30 panel A gel electrophoresis result, panel B pMOD-HSV1tk map. According to the 
standard size of DNA ladder and the pMOD-HSV1tk plasmid map, HSV1tk gene showed the 
exact size as shown in the map .The size of linearized plasmid DNA is 3280bp, size of DNA 
fragments from digested DNA with Nco-I and Nhe-I are 1255-116=1139 (single cut), 3280-
1139=2141 (double cut). 
 
 
Figure 31 western blot result of pMOD-HSV1tk Ecoli lysate showed HSV1TK enzyme of 
different masses from total protein of Ecoli lysate. 
 
HSV1 TK protein was purified from pMOD-HSV1tk Ecoli to be used as a positive control for 
western blot assays. Different concentrations of the primary antibody and different amounts of the 
protein were tested by western blot to choose the right mass of protein that can be loaded for 
western blot assays (figure 32). 
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Figure 32 western blot result of purified HSV1TK enzyme, panel A 2µg of  HSV1TK enzyme 
was tested against different concentrations of primary antibody. To obtain single band without 
nonspecific binding 1:10,000 concentration was selected for the following western blot assays 
(panel A). Panel B different masses of HSV1TK enzyme were tested against the chosen primary 
antibody concentration. Panel C showed HSV1TK signal quantification at different masses. Based 
on these findings 0.5 µg was selected for following western blot assays. 
 
5.2.2.2. Selection of stable transduced Jurkat, HEK 293 and 4T1 cells 
Before T lymphocytes were transduced with HSV1tk lentiviral vector, stable transduction was 
performed with HEK 293, Jurkat and 4T1 cell lines. These cells can be cultured for long periods 
of time; therefore they are suitable to be selected using Blasticidin selection marker, which 
requires 14 days of incubation. T lymphocytes on the other hand are a primary cell line and they 
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can be cultured only for 10 to 13 days. The reason to create stable cell lines was to compare the 
uptake of T lymphocytes to stable transduced Jurkat cells and estimate the transduction efficiency 
of T lymphocytes based on that.   
To create stable cell lines, cells were first incubated with different concentrations of Blasticidin 
for 14 days as described previously. This experiment was done to select the optimum 
concentration that will end up with zero viability of non-transduced cells. This optimum 
concentration was chosen to select stable transduced cells post transduction.  
Figures 33, 34 and 35 presented the % of viability of Jurkat, HEK and 4T1 cells respectively. 
Jurkat cells showed 0% of viability at 2µg/ml of Blasticidin concentration at day 14 of incubation, 
while HEK cells were more resistant, they were at 0% of viability at 10µg/ml at day 14. 4T1 cells 
showed 0% of viability at 8µg/ml concentration at day 14. 
These concentrations were chosen for stable transduction selection and were added to cells on day 
5 post transduction.  Cells were incubated at the selected concentration of Blasticidin for more 
than one month. RT-PCR and western blot assays were performed on the transduced cells post 
Blasticidin selection. 
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Figure 33 Panel A bright field images taken by fluorescent microscope of Jurkat cells at different 
concentrations of Blasticidin, cells are not able to proliferate and produce colonies in Blasticidin 
compared to 0 concentration. Panel B the % of viability of jurkat cells at different concentrations 
of Blasticidin on days 3 and 14 of incubation. At 2µg/ml on day 14 of incubation cells were at 0% 
of viability. 
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Figure 34 panel A bright field images of HEK 293 cells. The % of viability of  HEK 293 cells at 
different concentrations of Blasticidin on days 7 and 14 of incubation (panel B), even at 8µg/ml of 
Blasticidin concentration on day 14 of incubation, cells showed about 11% viable cells. Panel C, 
cells were incubated with 0 and 10 µg/ml of Blasticidin and the viability was tested on days 
3,7,10 and 14 post incubation. The 0% of viability for HEK cells was at 10µg/ml on day 14 of 
incubation. 
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Figure 35 panel A bright field images of 4T1 cells at different concentrations of Blasticidin. Panel 
B the % of viability of 4T1 cells at different concentrations of Blasticidin on days 1, 7 and 14 of 
incubation. At 8µg/ml on day 14 of incubation  
cells were at 0% of viability. 
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5.2.2.3. Verfication of HSV1tk gene expression by RT-PCR and westren blot 
To verify that Jurkat , HEK 293 and 4T1 cells are transduced with HSV1tk, RT-PCR and westren 
blot assays were performed as described previuosly. Figure 36 shwed RT-PCR result of the three 
cell lines.  
 
  
 
 
Figure 36 Panel A RT-PCR result showed HSV1tk gene in the transduced cells. Lane 1 and 2 
used as positive controls. Lane 1 is the pMOD-HSV1tk DNA (bacterial vector), lane 2 is pLenti6-
UBC-V5-HSV1tk (viral vector). Acording to the DNA ladder both lanes are between 1.6 and 1 kb 
and the expected size is 1.2 kb.  Lane 3    Jurkat cell cDNA control, Lane 4    Jurkat cell cDNA 
transduced with HSV1tk lentivirus. Lane 5    HEK cell cDNA control. Lane 6 HEK cell cDNA 
transduced with HSV1tk lentivirus. Lane 7 4T1 cell cDNA control. Lane 8 4T1 cellcDNA 
transduced with HSV1tk lentivirus. Panel B the expression ratio of HSV1tk/Beta Actin, JC= 
Jurkat cells, C= control, TD=transduced. 4T1 cells exhibit the higher ratio compared to jurkat and 
HEK cells. There is significant differenc between transduced 4T1 and both Jurkat and HEK ( p< 
0.05) but no significant difference between Jurkat and HEK cells. 
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Figure 37 western blot result showed HSV1-TK enzyme expressed in the transduced cells. 
1 = the purified HSV1TK protein, 2 = untransduced  jurkat cells, 3 = transduced jurkat cells, 4 = 
untransduced HEK cells, 5 = transduced HEK cells, 6 = untransduced 4T1 cells, and 7 = 
thransduced 4T1 cells (300µg of total protein of cell lysate was loaded) (panel A). 
Panel B showed the normalized signal of HSV1TK to beta-actin. 
 
5.2.2.4. 
124 
I [ FIAU ] uptake by transduced Jurkat, HEK 293 and 4T1 cells 
The uptake of 
124 
I-[FIAU] by transduced Jurkat, HEK 293 and 4T1 cells was investigated by 
incubating these cells with 
124 
I-[FIAU] for 1, 2, 4 and 18 hours as described previously. Figure 38 
panels A, B and C demonstrated the uptake results of these cells. Transduced Jurkat cells showed 
gradual increase in the uptake which was most pronounced at 18 hours (panel A). For HEK cells 
there was no significant differences in its uptake at 1, 2 and 4 hours, but was more obvious at 18 
hours (panel B). 4T1 cells showed higher uptake at all time points, they showed the maximum 
uptake among the three cell lines (panel C). 
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Figure 38 [
124 
I] FIAU uptake in transduced Jurkat cells (panel A), HEK cells (panel B) and 4T1 
cells (panel C). 4T1 cells showed the maximum uptake among the three cell lines at the different 
time points. 
 
 
HEK 293 cells 
A 
B 
C 
113 
 
5.2.2.5. PET imaging of 4T1 tumor 
Transduced 4T1 tumor was implanted in a number of animals and imaged at different time points 
as shown in figure 39. 
 
Figure 39 4T1 wild type tumor (A, B) on the left flank of a mouse imaged 1 hour (A) and 24 
hours (B) post injection of 
124
I-FIAU, shows the radiotracer completely clearing from the tumor 
(2.87 %ID/g to 0 %ID/g ). Whereas, the HSV1-tk stably transduced 4T1 tumor (C, D) in the left 
flank of another mouse shows the tumor activity to retain the radiotracer from 2.54 %ID/g at 1 
hour (C) to 1.05 %ID/g after 24 hours (D). Also seen are the stomach (3.83 %ID/g) and the 
thyroid (21.2 %ID/g). 
 
5.2.2.6. T-lymphocytes transduction 
5.2.2.6.1. T lymphocytes proliferation and viability before and after transduction 
IL2 or IL7/15 T lymphocytes were transduced on day 3 post ex vivo activation and expansion 
with different MOIs (10, 5, 2, 1, 0.2 and 0.03) as described previously.   
At MOI of 10, the viability of T cells was very low (almost 90% of cells died). At MOI of 5 and 
2, the % of viability was less than 40% (figure 40 panel A). However at MOI 1, 0.2 and 0.03, 
the % of viability was in average of 80% (figure 40 panel B). Cell proliferation was assessed by 
calculating the fold increase in cell number (comparing cell number every other day post 
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transduction to the cell number immediately post activation by B/I). Figure 40 demonstrates cell 
proliferation of IL2 or IL7/15 cells at MOI of 1. There are no significant differences (p > 0.05) 
between transduced and untransduced cells post transduction.  Based on this result, MOI of 1 was 
chosen for the following experiments.   
 
 
  
 
Figure 40 the % of viability of IL2 or IL7/15 at MOI of 2 and 5 (panel A), cell viability at MOI of 
2 decreases to less than 60% on day 3, 6 and become about 20% on day 9 post transduction. 
While at MOI of 5 at days 3, 6 and 9 decreases to be less that 30%. At MOI of 1, 0.2 and 0.03 the 
average viability about 80% (panel B). 
 
 
0
20
40
60
80
100
120
IL2 MOI=0 IL2 MOI=2 IL2 MOI=5 IL7/15 MOI=0 IL7/15 MOI=2 IL7/15 MOI=5
%
 o
f 
V
ia
b
il
it
y 
Day 3
Day 6
Day 9
0
20
40
60
80
100
120
%
 o
f 
V
ia
b
il
it
y
 
Day 3
Day 7
A 
B 
115 
 
 
  
 
 
 
5.2.2.6.2. Confirmation of HSV1tk gene expression in transduced T cells 
Based on the viability results, transduced cells at MOI of 1, 0.2 and 0.03 were analyzed using 
quantitative real time-PCR and western blot on day 5 post transduction to verify that HSV1tk 
gene has been integrated to cells genome via the lentiviral vector. Figure  42 shows the expression 
ratio of HSV1tk to Beta Actin; at MOI of 1, IL2 cells showed the highest expression ratio and it is 
significantly different (p<0.05) from IL2 cells at MOI of 0.2, 0.03 and IL7/15 cells at all three 
MOIs. With IL7/15 cells at the three MOIs showed no significant differences in the expression 
ratio.  
To test the HSV1tk expression, T cells lysate was prepared from IL2 or IL7/15 cells. Total protein 
in the cell lysate was determined using protein assay kit, and then 300µg was used for western 
blot assay (figure 43).  
Figure 41 fold increase in cell number for transduced (TD) and untransduced (UNTD) IL2 
or IL7/15 cells at MOI of 1(transduction was done on day 3 post ex vivo expansion). No 
significant differences between TD and UNTD cells. 
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Figure 42 the expression ration of HSV1TK to Beta actin in IL2 or IL7/15 cells at different MOIs. 
At MOI of 1 IL2 cells shwed the higher expresion ratio. While IL7/15 cells showed almost same 
ratio for all MOIs. 
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To know the changes in the HSV1tk expression over time, RT-PCR was performed on day 
1, 3, 5 and 7 post transduction at MOI of 1 as described previously. The result showed that the 
highest expression for both IL2 and IL7/15 cells was at days 1 to day 3; after that the expression 
decreased with time (figure 44).  IL2 cells showed higher expression than IL7/15 cells on days 1 
and 3 while on days 5 and 7, both cells were similar in their gene expression. 
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Figure 43 western blot results of transduced IL2 or IL7/15 cells at MOI of 1, 0.2 and 0.03.  
Based on the linear relationship of the purified HSV1TK  (panel C) the HSV1TK mass was 
calculated as illustrated in panel D. IL2 cells at MOI of 1 showed the highest expression of 
HSV1TK and this result is consistent with RT-PCR result. 
C 
D 
118 
 
  
 
Figure 44 the expression ratio of HSV1tk to Beta Actin at days 1, 3, 5 and 7 post transduction. 
IL2 cells showed higher expression than IL7/15 cells. Moreover day 1 and day 3 showed the 
higher expression for both cells. Based on this result transduced cells were used for the in vivo 
and ex vivo studies on day 3 post transduction. 
 
5.2.2.6.3. Interferon- γ protein release before and after T cell transduction 
To test if there are any differences in the ability of IL2 or IL7/15 cells to produce interferon- γ 
before and after transduction, interferon-γ release assay was performed on day 3 post transduction 
at MOI of 1 as described previously. Figure 45 represents the result; IL2 cells produce more 
interferon-γ protein than IL7/15 cells. This result is consistent with our previous result when we 
tested the effect of DiR labeled cells on cell protein production. Moreover, there are no significant 
differences (p > 0.05) in the amount of the interferon-γ released from cells before or after 
transduction. However there are significant differences between nil cells and control (C) or 
transduced (TD) cells (Nil cells are T cells incubated alone, control cells are untransduced or 
transduced cells incubated with irradiated 4T1 tumor cells).  
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Figure 45 the production of interferon γ protein from transduced and untransduced cells. 
Nil is stated for cells that were incubated alone. Other cells were incubated with 4T1 tumor cells 
to stimulate cell to release interferon γ in their supernatant. No significant differences (p<0.05) 
were observed before and after transduction for both cell groups. 
 
5.2.2.6.4. Cell phenotype before and after T cells transduction 
 
Cell phenotype was tested by flow cytometry before and after transduction to investigate if there 
is any effect of the transduction on cell phenotype. On day 3 post transduction (MOI=1), cells 
were double stained for either CD8/CD69 or CD8/CD62L. CD8 is the marker for cytotoxic T 
cells, CD69 is the marker for activated T cells and CD62L is also called L-selectin acts as a 
"homing receptor" for T lymphocytes to enter secondary lymphoid tissues via high endothelial 
venules. IL7/15 cells showed higher population of activated cytotoxic T cells than IL2 cells. No 
significant differences (p<0.05) between transduced and untransduced cells in the % of 
CD8/CD69 or CD8/CD62L populations was observed (figure 46).  
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Figure 46 flow cytometry of IL2 and IL7/15 cells phenotype before and after transduction stained 
for CD8/CD69 or CD8/CD62L. No significant difference between transduced and untransduced 
cells for both cell groups (the % population of positive staining for CD8/CD69 or CD8/CD62L 
indicated in blue color).  
 
 
5.2.2.6.5. [ 
124
I] FIAU  uptake by T lymphocytes 
 
To test the HSV1TK activity, transduced T cells (at MOI of 1 at day 3 post transduction) were 
incubated for 1,4, and 18 hours with [
124
I]-FIAU at activity of 1µci/ml. Figure 45 showed the  
uptake result. Transduced Jurkat cells were test along with transduced T cells. The uptake of IL2 
and IL7/15 cells looks comparable but less than transduced Jurkat cells. The reason is that the 
transduction efficiency of Jurkat cells is 100%   as they were incubated with Blasticidin for 
selection more than one month as described previously (they are 100% transduced). While the 
transduction efficiency of T cells is lower than 40% compared to Jurkat cells as demonstrated in 
the uptake result (figure 47). The HSV1TK protein concentration was assessed after 
124
I [FIAU] 
uptake by lysate cells and calculate the total protein concentration using protein assay kit as 
described previously. Figure 48 showed the result, Jurkat has a higher concentration than 
transduced T cells. 
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Figure 47 the % uptake of [ 
124
I] FIAU  by transduced T cells along with stable transduced jurkat 
cells. the transduction effecency of Jurkat cells is 100 % while T cells compared with Jurkat cells 
shwoed less the 40% of cells are transduced. 
 
 
 
 
Figure 48 transduced cells protein (total cell protein including HSV1TK) concentration post [ 
124
I] 
FIAU  uptake. Jurkat cells (TDJC) showed higher protein concentration than T cells especially at 
18 hours. There is significant differences (p<0.05) between protein concentration of Jurkat 
compared to T cells at 18 hours. 
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5.2.2.6.6 Biodistribution study  
 
Transduced T cells were labeled with DiR and injected into 12 animals bearing 4T1 tumor (6 for 
IL2 cells and 6 for IL7/15). Another two groups of animals (4 in each) were injected with DiR 
labeled T cells to be used as controls for PET imaging and biodistribution study. Fluorescent and 
PET imaging were carried out for two weeks. Animals were dissected for biodistribution study on 
day 3 and day 10 post 
124
I [FIAU ]  ( i.v. injections at activity of 200-300 µci / animal).  All 
tissues were taken for counting by gamma counting system. On day 3 both IL2 and IL7/15 cells 
showed similar % injected dose/tissue (%ID/tissue); spleen was the highest then liver, lymph 
nodes, tumor, and bone/bone marrow (femur + sternum) (figure 49 panel A).  The DiR animal 
groups were dissected for counting (panels B and C). In both DiR groups (IL2 or IL7/15) % 
ID/tissue was very low compared to transduced (TD) IL2 or IL7/15 groups. This was expected, 
because DiR groups are animals were injected with untransduced DiR cell.   
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Figure 49 biodistribution study of transduced IL2 and IL7/15 animals on day 3 post  
124
I [FIAU ]  
injections (panel A). Both groups show similar %ID/tissue in all tissues. Panel B and C both 
groups were compared to DiR group. There are significant differences between TD groups and 
DiR groups (p< 0.05) in %ID/tissue in all tissues. Values expressed as %ID/gm ± SEM (n=3). 
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5.2.2.6.7 Detection of HSV1TK at different organs by western blot 
To confirm the localization of transduced T cells at tumor site and other organs as shown in the 
Biodistribution study, western blot was performed to detect HSV1TK enzyme as shown in figure 
50. 
 
Figure 50 the western blot result of organs post transduced T cell injections. 
1= lymph nodes, 2= 4T1 tumor, 3= lungs, 4= liver, 5= spleen and 6= control tumor (from animals 
not injected with untransduced T cell). HSV1TK enzyme is clearly shown at these organs beside 
the tumor which is consistent with the fluorescent data and Biodistribution study result. (green 
color is Beta Actin, and red is Viral Thymidin Kinase (VTK)) 
 
5.2.2.6.8 4T1 tumor metastasis and T cells trafficking study. 
Our objective from this study is to compare the trafficking pattern of T cells to the primary tumors 
versus tumor metastasis. As explained previously, 4T1 tumor cells were transduced successfully 
with HSV1tk RG and implanted in number of animals at the abdominal mammary fat pad or in 
the right flank of the animal. Unfortunately tumors in the fat mammary pad did not grow well 
compared to untransduced cells implanted as a control into the left flank of the animals and most 
of the tumor was necrotic. Tumor volume measurements (figure 51) showed that fat mammary 
pad tumors (transduced 4T1 cells) did not grow well compared to the control tumor in the left 
flank of the animal consequently, no metastases were detected in PET imaging post [ 
124
I] FIAU 
injections in the third and fourth weeks post tumor implantation.  On the fourth week post tumor 
implantation and post 24 hours of [ 
124
I] FIAU injections, Biodistribution study was conducted as 
shown in figure 52 (A and B). As explained before the activity at each organ expressed 
                                                      
    1        2       3       4       5      6      VTK (41KD) 
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in %ID/gm of tissue. Intestine showed the highest %ID/gm then liver and stomach due to the 
clearance of [ 
124
I] FIAU from the body. Only the right flank tumor showed higher %ID/gm 
compared to the wild type tumor (left flank tumor) (figure 52 A) and also the mammary fat pad 
tumors showed about 2% of  %ID/gm may some tumor cells are alive and still express HSV1TK 
protein (figure 52 B).  
 
Figure 51 tumor volume measurements at different time post transduced and untransduced 4T1 
tumor implantation. Abdominal mammary fat pad (MFP) did not grow  
Well compared to left and right flank tumors.  
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Figure 52 Biodistribution studies at 24 hours post 
124
I FIAU injections. Panel A Biodistribution 
study from animals that had MFT tumors in the abdominal region. High % ID/gm was detected at 
the intestine, liver, stomach and tumor. Panel B Biodistribution study from animals implanted 
with flank tumors. The right flank tumor (transduced tumor) showed higher %ID/gm than the left 
flank tumor (wild type tumor). Values expressed in %ID± SEM. 
 
Along with the Biodistribution study, western blot was performed from tumor, spleen, liver, 
lungs, brain and lymph nodes. The result (figure 53) showed HSV1TK protein only in the tumor 
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tissues and not in the other tissues, indicating, no TK 4T1 (transduced 4T1) cells localized at 
these organs. 
 
Figure 53 western blot result of tissues after 4 weeks of transduced 4T1 tumor implantation in the 
abdominal mammary fat pad. 1 is the purified HSV1TK protein, 2 is wild type 4T1 tumor, 3 is 
transduced 4T1 tumor, 4 to 8 are lungs, brain, lymph nodes, liver and spleen. 
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Chapter Six:Discussions 
 This study demonstrates two different labeling methods to monitor T lymphocytes that 
are sensitized to 4T1 breast carcinoma tumor, then activated and expanded in vitro and adoptively 
transferred to recipient mice. First method is direct labeling with NIR probe (DiR) for optical 
imaging. Although the use of DiR as a labeling probe for in vivo studies in AIT is still in its initial 
experimental stages; several studies have been successfully applied DiR to label cells and gather 
useful information about cell migration and localization in vivo in mice and rats. Kalchenko et al 
[64] successfully used DiR to label human leukemia G2L cells, mouse T lymphocytes, and rat red 
blood cells for in vivo studies, Granto et al [65] also used DiR to label fibroblast cells to target 
ovarian cancer. In another study by Jing Ruan et al [66], used DiR to label embryonic stem cells 
to target gastric cancer and they found that this labeling technique has great potential in molecular 
imaging application to track cells in vivo. The properties of NIR-DiR as lipophilic dye make it 
ideal for staining cytoplasmic membrane. The conclusion of these different studies and other 
studies used DiR to label and track different cells showed that DiR had no significant influence on 
the biological properties of cells.  
In this study we have used DiR to label ex vivo activated T lymphocytes grown in 
different cytokines (IL2 or IL7 and IL15) and monitor their migration and trafficking in vivo at 
different time points as shown in our results. Cell viability, proliferation and the production of 
interferon-γ cytokine were assessed before and after labeling with DiR.  The results of these 
assays showed that DiR is a compatible probe for cell labeling and in vivo monitoring and does 
not cause any changes in cell proliferation, viability or function.  
Our in vivo studies showed that, the localization of 4T1 tumor specific T-lymphocytes 
occurred within 24 hours after intravenous administration of the activated cells. Although cells 
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grown in IL2 showed detectable signal starting from 2 hours (figure 21 A) while for cells grown 
in IL7/15, the signal was seen at 24 hours. Smironv and his colleagues [61] studied in vivo T cell 
trafficking by direct labeling with SPIONs for MRI imaging. Their results showed relatively 
lower signal in the spleen at 24 hours than at 48 hours. The signal at spleen and tumor then 
peaked at 72 hours.  This result was consistent with our results, both IL2 and IL7/15 cells peaked 
at the tumor site at 72 hours. In another study done by Pittet and colleagues [67] it was shown that 
tumor specific cytotoxic T-lymphocytes directly labeled with [
111
In]- Oxine (2.8 days half-life) 
for SPECT imaging, started localizing at the tumor site within the first 24 hours and continued to 
increase over time and were at peak when imaged at 72 hours post injection. Our results are 
consistent with these results; and moreover, the NIR signal from the T-cells at the tumor site 
persisted for nearly three weeks after labeling and administration. This demonstrates the 
suitability of this method for relatively long-term studies of cell trafficking in animal models of 
disease. 
To confirm that the signal we observed at the tumor site is associated with DiR labeled T 
lymphocytes, cell lysate was prepared using freezing and thawing protocol following viability test 
to ensure all cells were lysed, then cell lysate was injected i.v. in number of animals at the same 
experiment viable cells were also injected i.v. to another group of animals. MSFI was carried out 
at different time points; the result showed that no signal was detected at the tumor site in the 
animal group injected with cell lysate. This confirms two important points: first the specificity 
and persistence of DiR as labeling probe for T cells, second, the specificity of viable 4T1 specific 
T cells to localize at the tumor site. Moreover, to test 4T1 specific T cells specificity toward 4T1 
tumor, Meth A tumor was used as control tumor and from our results no localization of 4T1 
specific T cells was observed at Meth A tumor. This specificity has been shown in a number of 
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studies that used different cytokines to activate ex vivo T cells isolated from tumor or draining 
lymph nodes (DLN) then adoptively transferred to tumor bearing hosts which cause regression of 
the tumor over specific period of time [68]. In our studies we used DLN T cells activated in 
Bryostatin 1 and Ionomycin (B/I) for 18 hours then grown in different cytokines (IL2 alone or 
combination of IL7 and IL15) for 10 to 12 days. This activation method has been shown by 
Esther Cha et al [26] for AIT in 4T1 breast tumor and by Hanh et al [23] for AIT in B16 
melanoma tumor and their results showed significant regression of tumor depending on 
adoptively transferred cell number. Bryostatin 1 selectively activates protein kinase C and 
Ionomycin increases intracellular calcium with both mimicking cell signaling through CD3 T cell 
receptor (TCR) and leading to activation and proliferation of T cells. Chin et al [69] has shown 
that tumor sensitized draining lymph nodes (DLN) cells activated ex vivo with B/I are capable of 
inducing antigen-specific regression in murine mammary tumors. The same group demonstrated 
that B/I selectively stimulates and activates T cells expressing low levels of lymph node homing 
receptor (L-selectin
low 
) or ( CD62L
low
) which is a marker associated with sensitized T cells and 
promote their trafficking to other locations [70].  
We also observed that the labeled T-cells home into lymphoid organs such as bone 
marrow and spleen, from ex vivo imaging of dissected organs. In order to examine whether these 
labeled T-cells are capable of moving out of these compartments and home into a tumor site at a 
subsequent tumor challenge, in one set of experiments, we first injected the labeled 4T1 specific 
T-cells in non-tumor bearing mice. One week later, these animals were imaged just before and 
then after the 4T1 tumor cells were implanted. DiR labeled 4T1 specific T-cells were detected in 
the tumor cell injection site as early as 2 hours after tumor cell implantation. The signal at the 
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tumor site persisted for another two weeks, confirming that the labeled T-cells can move out of 
the lymphoid organs to the site of a fresh antigen challenge.  
Labeling of T-cells with near-infra red (NIR) fluorescent dyes for AIT has been reported 
in a few recently published studies. Du and coworkers [71] investigated the trafficking of DiR 
labeled human cytokine-induced killer (CIK) cells and cytotoxic T lymphocytes (CTLs) in a nude 
mouse model of orthotopic gastric carcinoma. In their study, the fluorescent signal peaked at 48 
hours and was observed at the tumor site up to two weeks after infusion. The cell proliferation of 
labeled cells was comparable to unlabeled cells, similar to our observations. Moreover, after 
labeling the T-cells with a range of DiR concentrations (3.5, 14, 56, 224 and 320 µg/ml), we 
tested the cell viability using two different methods to ensure good cell tolerance to the dye before 
moving to the in vivo studies. T-cell function was also tested by measuring IFN-γ release in 
response to tumor antigen, and our results showed no significant detrimental effect of the labeling 
probe on cell proliferation, viability or function. Also, this allowed us to use a high DiR 
concentration (320 µg/ml) in the labeling solution. Our study also demonstrates signal persistence 
in the labeled T-cells even 3 weeks post labeling under the in vivo conditions of living mice.  
The in vivo biodistribution of the labeled T-lymphocytes, in this study, was consistent with 
other studies. The signal was detected in lungs, spleen, liver, bone marrow and was observed at 
the tumor site at 24 hours and remained stable for up to 21 days when the labeled cells were 
infused into mice bearing established 4T1 breast carcinoma tumors. To ascertain whether the 
source of signal around the tumor was coming from labeled T-cells, double staining of tumor with 
CD69 (T cell activation marker) and F4/80 (macrophage marker), was performed. The confocal 
microscopy images revealed presence of activated T cells only in sections from mice bearing 4T1 
tumor injected with ex vivo activated T cells and not in tumor sections from control 4T1 bearing 
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mice. On the other hand, the presence of macrophages was observed in tumor sections from both 
groups of animals as expected. Moreover, flow cytometry method was used to investigate whether 
DiR labeled T cells were engulfed in vivo by macrophages or DiR transferred to other immune 
cells. The result showed that no connection between DiR and macrophages or other immune cells, 
representing that DiR specifically labeled ex vivo activated T cells and the signal we detected is 
linked to only DiR labeled T cells.  
In conclusion, this method shows that, labeling of 4T1 specific T lymphocytes with DiR, a 
NIR fluorescent cell membrane marker, provides an easy to use, stable and convenient tool for in 
vivo imaging of T-lymphocytes whilst retaining their inherent function. Use of DiR or similar cell 
membrane markers will be useful for investigating lymphocyte trafficking following their ex vivo 
sensitization, activation and proliferation. This method could also be used to non-invasively 
monitor the trafficking of other cell types.  
The second method in this study was indirect labeling of T cells using PRG system 
(HSV1tk/ [
124
I]-FIAU). Initially HSV1tk gene was used as therapeutic or suicide gene in the 
application of gene therapy studies for different types of cancer. The first approaches developed 
to introduce HSV1tk as therapeutic gene was by Moolten at al [72]. In this approached they used 
Ganciclovir (GCV) as substrate for HSV1tk gene which was transduced to a number of tumors. 
The result of phosphorylation showed cell toxcicity and death to transduced tumor cells. Since 
that time more studies were developed to image HSV1tk/GCV as reporter system for gene 
therapy [73]. The principle of in vivo imaging using HSV1tk as reporter gene for imaging was 
first demonstrated using 
14
C 2- fluoro-5-methyl-1-ß-D- arabinofuranosylluracil ([
14
C ]-FMAU)  
by Saito et al in 1982 [74 ]. Later in 1995, Tjuvajev et al employed ([
123/124
I ]-FIAU) as reporter 
probe for HSV1-tk reporter gene for brain tumors [75]. Subsequently they demonstrated for the 
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first time that (HSV1tk/ [
124
I ]- FIAU) system  is highly specific as noninvasive imaging system 
for clinical PET imaging due to its ability  to image the distribution and the level of gene 
expression [76].  
 FIAU is a thymidine nucleoside has been used as an antiviral agent against hepatitis 
viruses [77]. FIAU has advantages of being imaged by different imaging modalities such as 
SPECT and PET due the ability of radiolabeling with 
123/125/131 
I or 
124
I. Moreover, it is a specific 
substrate for viral thymidine kinase (VTK) enzyme that is expressed by HSV1tk gene, 
mammalian TK has no ability to phsphorylate FIAU.  In comparison to other reporter probes such 
as FHBG or FHPG it has greater sensitivity and lower abdominal background radioactivity [78]. 
In this study we used HSV1tk/ [
124
I ]- FIAU system for the indirect labeling method of T cells due 
its mentioned advantages . 
Our results demonstrate successful transduction in Jurkat, HEK293, 4T1 and T cells. This 
was confirmed by RT-PCR, western blot and uptake studies.  One problem we faced is that the 
HSV1tk lentivirus we used showed some toxicity to T cells. This lead us to reduce the ratio of 
virus particles to cells number during the transduction; consequently the transduction efficiency 
was low and couldn’t be detected by PET imaging. Toxicity of reporter gene imaging has been 
shown in a number of studies [79] and it is one of the limitations of this method. Another 
limitation is that, the level and persistence of gene expression was not enough to monitor our 
transduced T cells.   Even though our ex vivo data showed successful transduction of T cells, but 
the scenario in vivo was different. Only few cells were transduced and the percentage of cells at 
each organ including tumor site was lower than 5% (this was shown in flow cytometry data) from 
the total 10 million cells were injected into each animal. Also our reporter gene promoter was an 
ubiquitin promoter which has limited amount of gene expression compared to other promoters 
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like cytomegalovirus (CMV) promoter. The rationale of using ubiquitin promoter is that it doesn’t 
have a silencing problem with time, and our goal was to monitor T lymphocytes for long periods 
of time. However our biodistribution data showed results consistent with optical imaging data, 
the %ID/gm was higher at spleen, lungs, liver and tumor. Also Western blot assay from these 
tissues showed the presence of HSV1TK enzyme at each tissue.  
In conclusions, to improve our reporter gene method, more effective HSV1tk lentivirus 
has to be constructed. The new constructed reporter gene should include GFP protein as a marker 
to accurately estimate cell transduction efficiency. This estimation method is more common and 
precise to know the exact percentage of transduced cells using flow cytometry or fluorescent 
microscopy. The promoter has to be chosen to result in a sufficient level of gene expression to 
successfully obtain good detection of signal for imaging.  
The last objective in this study was to monitor the localization of T cells at 4T1 tumor 
metastases. To achieve this objective, 4T1 cells were successfully transduced with HSV1tk and 
implanted in number of animals at the abdominal mammary fat pad. PET imaging was performed 
at third and fourth week post tumor implantation, but no metastases were detected.  From 
previous studies [80], abdominal mammary fat pad tumors more likely to spread in the abdominal 
region and do not show metastases at other regions of the animal body. Omar Rashid et al [80] 
has shown successful 4T1 tumor metastases model by implanting 4T1-luc2 (4T1 transduced 
tumor with luciferase reporter gene) orthotopically into chest mammary fat pad of  Balb/C mice 
under direct vision. After 10 days resection of the primary tumor was done and the tumor 
metastases were detected by biolumencent imaging at lymph nodes by day 8 after tumor 
implantation then to the lungs by day 12.   This method improves animal survival by decreasing 
the overall tumor burden, rapid increase in the metastases proliferation; decrease splenocyte 
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myeloid-derived suppressor cells (MDSCs) and increasing in CD8 and CD4 cells, suggesting 
potential improvement in the immunologic response against the tumor. 
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Chapter Seven Conclusion and Future Work 
This study was done to develop multi-modality molecular imaging to monitor in vivo 4T1 specific 
T cells, for adoptive immune cell therapy. Direct and indirect labeling methods were employed 
and studied. 
Direct labeling method using NIR DiR florescent probe  showed good results compared to the 
indirect labeling method using (HSV1tk/ [
124
I] FIAU) system. 
The following points can be highlighted from the indirect labeling method: 
 This method showed higher labeling efficiency (> 90%) compared to the indirect labeling 
method (≤ 30%). 
 No transfer of the DiR to other cells in vivo and ex vivo was observed. 
 DiR provides an easy to use, stable and convenient tool for in vivo imaging of T-
lymphocytes whilst retaining their inherent function in vivo and ex vivo.  
 In comparison to the indirect labeling method, direct labeling method showed valuable 
information about the trafficking and localizations of T cells grown in different cytokines 
 Indirect labeling method is limited by targeting or delivery of the reporter gene (RG) to 
cell under transduction, integration, activation, amount or level of RG (transduction 
efficiency), RG expression and persistence over time.  
 
Recommendations and future directions 
As the direct labeling method with DiR provides valuable data about the trafficking and 
localizations of DiR labeled T cells without any changes in cell proliferation, viability, and 
function, it is worthwhile to label DiR with 
124
I for PET imaging, or  
131
I for SPECT imaging over 
prolonged period of time. To achieve this, the radio-iodination strategy of DiR has to be robust 
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and must resist  dehalogination in vivo. Furthermore, the effect of radioactivity, per se, on cell 
proliferation and viability must be carefully addressed. 
 
To improve the indirect labeling method, more effective HSV1tk lentivirus should be constructed 
with GFP to accurately estimate the transduction efficiency. Furthermore, the new construction 
should not be toxic at the adequate level for the gene to be detected in the in vivo imaging. 
 
To develop successful breast cancer metastatic model, for the purpose of studying the 
migration pattern of labeled T cells to the metastases, it is highly recommended to follow Omer 
Rashid et al model [80]. This model as discussed previously improves animal survival by 
decreasing the overall tumor burden, rapid increase in the metastases proliferation; decrease 
splenocyte myeloid-derived suppressor cells (MDSCs) and increasing in CD8 and CD4 cells, 
suggesting potential improvement in the immunologic response against the tumor. 
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Appendix  
 
Research publications and conference presentations 
 
Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J. 
(2011, 2012 and 2013) Multi-spectral fluorescence imaging of adoptive immune cell therapy 
using cell membrane probe ( presented at the Massey Cancer retreat meetings with adding more 
data) 
 
Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J. 
(2013) Multi-spectral fluorescence imaging of adoptive immune cell therapy . J. Molecular 
Imaging (submitted) 
 
Youniss F, Gobalakrishnan S., Purnima Jose, Laura Graham, Collin Berry, Harry D Bear, Zweit J. 
(2011 ) Multi-spectral fluorescence imaging of adoptive immune cell therapy using cell 
membrane probe .Journal of Nuclear Medicine.52:pp1557.2011( presented at the SNM-2011 
meeting). 
 
Georgi Gurli, Gobalakrishnan S., Youniss F, Ekaterine Goliadze , Li Wang, Sammuel P .R 
obison, Zweit (2012) Molecular Imaging of dendritic cell tracking in vivo in a murine prostate 
cancer model (presented to AUA 2012 meeting) 
 
Youniss F, Ekaterine Goliadze, Gobalakrishnan Sundaresan, Li Wang, Georgi Gurili, Jamal 
Zweit. (2013) Non-invasive near-infrared imaging of dendritic cell trafficking in living mice. 
( presented to WMIC 2013 meeting as oral presentation) 
 
Submitted predoctoral molecular imaging scholar program application to SNMMI 2012(not 
funded) 
 
 
 
 
 
 
 
140 
 
References 
1. Michael O'Connor et al, Molecular breast imaging. Expert Rev Anticancer Ther. 2009 ; 
9(8): 1073–1080. 
2.  www.breastcancer.org. 
3. Andrew E Place et al.  The microenvironment in breast cancer progression: biology and 
implications for treatment. Breast Cancer Research. .2011; 13:227-238. 
4. Muaiad Kittaneh et al, Molecular profiling for breast cancer: comprehensive review. 
Biomarkers Cancer.2013; 5:61-69. 
5. K.A.Cadoo et al, Biological subtypes of breast cancer: current concepts and implications 
for recurrence patterns. QJ NUCLMED MOL IMAGING 2013; 57:312-321. 
6. Lin NU, Clinicopatholgic features,patterns of recurrence and survival amoung women 
with triple negative breast cancer in the national comprehensive cancer. Cancer 
network.2012; 118:5463-5472. 
7. Den R et al. Pattern of metastatic spread in triple-negative breast cancer. Breast cancer 
Res Treatment. 2009; 115:423-428.  
8. Ross JS et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER2 
therapy and personalized medicine. Oncologist. 2009;14: 320-368 
9. Salmon DJ et al. Use of chemotherapy plus monoclonal antibody against HER-2 for 
metastatic breast cancer that overexpress HER2. NewEngl. 2001;344:783-792. 
10. Hudis CA et al Trastuzumab mechanism of action and use in clinical practice. New Engl 
med.2007;357:39-51. 
11. Michail Lgnatiadis et al, Luminal breast cancer: from biology to treatment. 
Nature.2013;10:494-506. 
12. Creighton C J et al. The molecular profile of Luminal B breast cancer.Biologic.2012; 
6:289-297. 
13. Valentina Guarner et al. The curability of breast cancer and the treatment of advanced 
disease. European Journal of Nuclear Medicine and Molecular Imaging.2004;31:149-161. 
14. Stephen E Wright et al.  Immunotherapy of breast cancer. Expert Opin. Biol. Ther. 2012; 
12(4):479-490. 
15. Shannon Puhalla et al, Hormonal therapy in breast cancer: A model disease for the 
personalization of cancer care. Molecular oncology. 2012:1-15. 
16. William Coley et al. A commotion in the blood: life,deth,and the immune system.New 
work: Henry Holt.544pp.  
17. Korngold R et al. Lethal graft-versus-host diseas after bone marrow transplantation across 
minor histocompatibility barrier in mice. Prevention by removing mature T cells from 
marrow.  Exp. Med.1978; 148:1687-1698. 
18. Bernhard H, et al. Adoptive transfer of autologous HER2-specific cytotoxic T 
lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol 
Immunother. 2008;57: 271-280. 
19. Alan B. Frey, Ngozi Monu. Signaling defects in anti-tumor T cells. Immunological 
reviews. 2008; 222: 192-205. 
20. Robert A Weinberg. The biology of cancer. Published by Garland Science, Taylor& 
Francis Group, LLC UK 2007. 
21. Janeway’s. Immunobiology. Garland Science, 2012. 
141 
 
22. Mark E Dudly and Steven A. Rosenberg. Adoptive-cell-transfer therapy for the treatment 
of patient with cancer. Nature review.2003; 3:666-675. 
23. Hahn K.Le. Laura Graham. Catriona H.T. Miller. Maciej Kmieciak. Massoud H. Manjili. 
Harry Douglas Bear. Incubation of antigen-sensitized T lymphocytes activated with 
bryostatin 1 + ionomycin in IL-7+IL-15 increase yield of cells capable of inducing 
regression of melanoma metastases compared to culture in IL-2. Cancer Immunol 
Immunother.2009; 58:1565-1576. 
24. Davies C et al. Relevance of breast cancer hormone receptors and other factors. Lancet. 
2011; 378;771-784. 
25. Fisher B et al. Reanalysis and results after 12years of follow-up in a randomized clinical 
trial in the treatment of breast cancer. N Engl J Med 1995;333:1456-1461. 
26. Esther Cha. Laura Graham. Masoud H. Manjili. Harry D.Bear. IL-7+ IL-15 are superior to 
IL-2 for ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater 
efficacy against tumor in vivo. Breast Cancer Res Treat.2009. 
27. C. Yee, J.A. Thompson, D. Byrd, S,R, Riddell, P. Roche, E. Celis, P.D.Greenberg. 
Adoptive T cell therapy using antigen- specific CD 8
+
 T cell clones for treatment of 
patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of 
transferred T cells. Mayo Clinic. 2002; 99: 16168-16173. 
28. Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered 
lymphocytes. Science. 2006; 314: 126-129. 
29. Qin Wang, Moshe Ornstein and Howard L Kaufman. Imaging the immune response to 
monitor tumor immunotherapy. Expert Rev.Vaccines. 2009; 8(10): 1427-1437. 
30. Christoph Domscke et al. Long-term survival after adoptive bone marrow T cell therapy 
of adavanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. 
Cancer Immunol Immunother. 2013; 62: 1053-1060. 
31. Stefan Stefanovic et al. Adoptive immunotherapy of metastatic breast cancer: present and 
future. Cancer Metastasis Rev. 2013;13:9452-9456. 
32. Michel Modo et al.  Noninvasive imaging of transplanted cells. Curr Opin Organ 
Transplant . 2008,13:654–658. 
33. Mankoff DA. A definition of molecular imaging. J. Nucl. Med 2007;48:18N, 21N. 
34. Hang Hong, Yunan Yang, Yin Zhang and Weibo Cai. Non-Invasive cell tracking in cancer 
and cancer therapy. Curr Top Med Chem. 2010; 10 (12): 1237-1248. 
35. Marybeth A. Pysz, et al. Molecular Imaging: Current Status and Emerging Strategies. Clin 
Radiol. 2010; 65(7): 500–516. 
36. Adrian Taruttise et al.Fast Multispectral Optoacoustic Tomography (MSOT) for Dynamic 
Imaging of Pharmacokinetics and Biodistribution in Multiple Organs. Plos One. 
2012;7:30491-30496. 
37. M. Srinivas et al. Imaging of cellular therapies. Advanced Drug Delivery Reviews.  2010; 
62:1080–1093. 
38. Giovannni Lucignani et al. Molecular imaging of cell-mediated cancer immunotherapy. 
Trends in Biotechnology. 2006; 24: 410-418. 
39. Elizabeth J Akins and Purnima Dubey. Noninvasive imaging of cell- mediated therapy for 
treatment of cancer. Journal of Nuclear Medicine. 2008; 49: 180-195. 
40. Inna Serganova et al. Reporter gene imaging: potential impact on therapy. Nuclear 
Medicine and Biology.2005; 32: 763-780. 
142 
 
41. Christopher R Parich et al. Fluorscent dyes for lymphocyte migration and proliferation 
studies. Immunology and Cell biology.1999; 77:499-508. 
42. Hirotatsu Kojima et al . Development of near-infrared fluorescent probes for in vivo 
imaging. The pharmaceutical society of Japan 2008;128:1653-1663. 
43. Giovannni Lucignani et al. Molecular imaging of cell-mediated cancer immunotherapy. 
Trends in Biotechnology. 2006; 24: 410-418. 
44. Vasilis Ntziachristos et al. Fluorscence imaging with near-infrared light: new 
technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-
208. 
45. Foster AE et al. In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration 
using IRDye800CW near-infrared dye. Appl. Opt 2008; 47:5944–5952.  
46. Inna Serganova et al. Human receptor genes: potential use in clinical studies. Nuclear 
Medicine and Biology. 2007;34:791-807. 
47. Dw Townsend. Physical principles and technology of clinical PET Imaging. Ann Acad 
Med Singapore 2004;33:133-145. 
48. Simon R Cherry Jamwes A Sorenson. Physics in nuclear medicine, third edition. Elsevier 
Science 2003.  
49. Swirski FK, et al. A near-infrared cell tracker reagent for multiscopic in vivo imaging and 
quantification of leukocyte immune responses. PLoS ONE 2007; 2: 1075. 
50. Mandl S, et al.. Understanding immune cell trafficking patterns via in vivo 
bioluminescence imaging. J. Cell. Biochem. Suppl 2002; 39:239–248. 
51. Jonathan Hardy, et al. Bioluminescence imaging of lymphocyte trafficking in vivo. 
Experimental Hematology. 2001; 29: 1353-1360. 
52. Matthias T Stephan et al. Theraputic cell engineering with surface-conjugated synthetic 
nanoparticles. Nature medicine. 2010; 16:1035-1041. 
53. Mathew L.Thakur, Antony W.et al. Indium-111-Labeled cellular blood components: 
mechanism of labeling and Intracellular location in human neutrophils. J Nucl Med 1977; 
18: 1020-1024. 
54. Elizabeth J. Read, Andrew M. Keenan, et al. In vivo traffic of Indium-111-oxine labeled 
human lymphocytes collected by automated apheresis.  J Nucl Med 1990; 31:999-1006. 
55. Simon R. Cherry, James A. Sorenson, Michael E. Phelps. Physics in nuclear medicine, 
third edition. Elsevier Science USA 2003.  
56. Carlo Botti, Donatella RM. Negri, Ettore Seregni et al. Comparison of radiolabeled human 
activated T lymphocytes. Eur J Nucl Med 1997; 24: 497-504. 
57. Adona N et al. Ex vivo cell labeling with 64Cu- pyruvaledhyde-bis(N4-
methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission 
tomography. Proc Natl Acad Sci. 2002; 99: 3030-3035. 
58. Dubey,P et al. Quantitative imaging of the T cell antitumor response by positron-emission 
tomography. Proc. Natl. Acad.Sci. 2003;100: 1232-1237. 
59. Su,H. et al. Quantitation of cell number by a positron emission tomography reporter gene 
strategy. Mol.Imaging Biol. 2004; 6: 139-148. 
60. Agger R, Petersen MS, Petersen CC, et al. T cell homing to tumors detected by 3D-
coordinated positron emission tomography and magnetic resonance imaging. J 
Immunother. 2007;30:29–39. 
143 
 
61. Smirnov P, Lavergne E, Gazeau F, et al. In vivo cellular imaging of lymphocyte 
trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn Reson 
Med. 2006;56:498–508. 
62. Elazabeth J. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl 
Med. 2008; 49:180-195. 
63. Sumitaka Hasegawa et al. Molecular MR imaging of cancer therapy: Ferritin transgene 
reporter takes the stage. Magn Reson Med Sci. 2010; 9: 37-47. 
64. Kalchenko V et al. Use of lipophilic near-infrared dye in whole-body optical imaging of 
hematopoitic cell homing. J Biomed Opt.2006; 11:050507.  
65. Granto D et al. In vivo imaging of the systemic recruitment of fibroblasts to the 
angiogenic rim of ovarian carcinoma tumors. Cancer Res.2007; 67:9180-9189. 
66. Jing Ruan et al. DiR-labeled embryonic stem cells for targeting imaging of in vivo gastric 
cancer cells. Theranostics 2012;2: 618-628. 
67. Pittet MJ, Grimm J, Berger CR, et al. In vivo imaging of T cell delivery to tumors after 
adoptive transfer therapy. Proc Natl Acad Sci U S A. 2007;104:12457-61. 
68. Johanna K. et al. Adoptive transfer of HER2/neu-specific T cells expanded with 
alternating gamma chain cytokines mediate tumor regression when combined with the 
depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008. 
69. Cynthia S Chin et al. Bryostatin /Ionomycin-Activated T cells mediated regression of 
established tumors. Jurnal of surgical research 2001;98: 108-115. 
70. Tuttle T M et al Activation and growth of murine tumor-specific T-cells have in vivo 
activity with bryostatin 1.Cancer Res,1992;52:548. 
71. Du X, Wang X, Ning N, et al. Dynamic tracing of immune cells in an orthotopic gastric 
carcinoma mouse model using near-infrared fluorescence live imaging. Exp Ther Med. 
2012;4:221-25. 
72. Moolten FL et al. Curability of tumors bearing herpes thymidine kinase genes transferred 
by retrovirus vectors. J Natl Cancer Inst.1990;82:297-300. 
73. Ronald Blasberg. PET imaging of gene expression. European Journal of cancer 
2002;38:2137-2146. 
74. Saito Y et al. Quantitative autoradiographic mapping of herpes simplex virus encephalitis 
with radiolabeled antiviral drug. Sciences. 1982;217:1151-1153. 
75. Juri G Tajuvajev et al. Imaging the expression of Transfected Genes in vivo. American 
Association for cancer research. 1995;55:6126-6132. 
76. Juri G Tjuvajev. Imaging virus thymidine kinase transfer and expression by positron 
emission tomography. Cancer research. 1998;58:4333-4341. 
77. Andreas Jacobs et al. Quantitative Kinetics of [124I] -FIAU in Cat and Man. J Nucl Med 
2001; 42:467–475. 
78. Juri Gelovani Tajuvajev et al. Comparison of radiolabeled nucleoside probes 
(FIAU,FHBG,and FHPG) for PET imaging of HSV1-tk gene expression. The Journal of 
Nuclear Medicine.2002;43:1072-1083. 
79. Kenneth Lundstrom. Latest development in viral vectors for gene therapy. Trends in 
biotechnology. 2003; 21:117-122 
80. Omar M Rashid et al. Resection of the primary tumor improves survival in metastatic 
breast cancer by reducing overall tumor burden. Surgery .2013; 153:771-778. 
 
 
144 
 
Vita 
 
Fatma Mousa Youniss was born on May 21th, 1973, in Elmarj, Libya, and she is a Libyan citizen. 
She graduated from  Elhurya High School, Elmarj, Libya in 1990. She received her Bachelor 
degree in Medical Technology from University of Derna, Libya in 1994.  Subsequently she 
worked as teaching assistant (TI) in the same university up to December 2000. In January 2001 
she was awarded scholarship from the high education ministry of Libya to study for master degree 
in Medical Physics in Malaysia. She obtained her master in 2004. From January 2004 to July 
2008 she was working as faculty member in the University of Derna teaching undergraduate 
students in Medical Technology School/ Radiology department. In 2008 she was awarded another 
scholarship for PhD in Medical Physics in USA. In August, 2009, she entered graduate school at 
Virginia Commonwealth University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
